Aytu BioPharma (AYTU) 10-K 27 Sep 22 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Jun. 30, 2022	Sep. 19, 2022	Dec. 31, 2021
Cover [Abstract]
Entity Central Index Key	0001385818
Document Type	10-K
Document Annual Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-38247
Entity Registrant Name	AYTU BIOPHARMA, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-0883144
Entity Address, Address Line One	373 Inverness ParkwaySuite 206
Entity Address, City or Town	Englewood
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80112
City Area Code	720
Local Phone Number	437-6580
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Entity Listing, Par Value Per Share	$ 0.0001
Trading Symbol	AYTU
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 38.2
Entity Common Stock, Shares Outstanding		62,432,727
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Amendment Flag	false
Auditor Name	Plante & Moran, PLLC
Auditor Firm ID	166
Auditor Location	Denver, Colorado

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Current assets
Cash and cash equivalents	$ 19,360	$ 49,649
Restricted cash	0	252
Accounts receivable, net	21,712	28,176
Inventory, net	10,849	16,339
Prepaid expenses	7,375	9,780
Other current assets	633	1,038
Total current assets	59,929	105,234
Property and equipment, net	3,025	5,140
Operating lease right-of-use asset	3,271	3,563
Intangible assets, net	70,632	85,464
Goodwill	0	65,802
Other non-current assets	766	465
Total non-current assets	77,694	160,434
Total assets	137,623	265,668
Current liabilities
Accounts payable and other	10,987	19,255
Accrued liabilities	44,187	57,234
Short-term line of credit	3,813	7,934
Current portion of debt	96	16,668
Other current liabilities	5,359	8,347
Total current liabilities	64,442	109,438
Debt, net of current portion	14,279	180
Other non-current liabilities	12,810	18,482
Total liabilities	91,531	128,100
Commitments and contingencies (Note 19)
Stockholders' equity
Preferred Stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding as of June 30, 2022 and June 30, 2021	0	0
Common Stock, par value $.0001; 200,000,000 shares authorized; shares issued and outstanding 38,578,825 and 27,490,412, respectively, as of June 30, 2022 and June 30, 2021	4	3
Additional paid-in capital	334,560	315,864
Accumulated deficit	(288,472)	(178,299)
Total stockholders' equity	46,092	137,568
Total liabilities and stockholders' equity	$ 137,623	$ 265,668

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Jun. 30, 2021
Preferred stock
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	38,578,825	27,490,412
Common stock, shares outstanding (in shares)	38,578,825	27,490,412

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Consolidated Statements of Operations
Product revenue, net	$ 96,669	$ 65,632
Revenue from Contract with Customer, Product and Service	Product	Product
Cost of sales	$ 44,386	$ 36,432
Gross profit	52,283	29,200
Operating expenses
Research and development	14,439	5,623
Selling and marketing	38,713	30,308
General and administrative	31,167	25,500
Acquisition related costs	0	2,919
Restructuring costs	0	4,886
Impairment expense	75,458	12,825
Amortization of intangible assets	4,067	6,009
Total operating expenses	163,844	88,070
Loss from operations	(111,561)	(58,870)
Other income (expense)
Other (expense), net	(862)	(2,050)
Gain (loss) from contingent consideration	1,760	4,459
Gain (loss) on extinguishment of debt	169	(1,569)
Gain on derivative warrant liability	211	0
Total other income	1,278	840
Loss before income tax	(110,283)	(58,030)
Income tax (benefit) expense	(110)	259
Net loss	$ (110,173)	$ (58,289)
Weighted average number of common shares outstanding - basic (in shares)	29,397,504	16,746,679
Weighted average number of common shares outstanding - diluted (in shares)	29,397,504	16,746,679
Basic net loss per common share (in dollars per share)	$ (3.39)	$ (3.48)
Diluted net loss per common share (in dollars per share)	$ (3.75)	$ (3.48)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning balance at Jun. 30, 2020	$ 1	$ 215,024	$ (120,010)	$ 95,015
Beginning balance (in shares) at Jun. 30, 2020	12,583,736
Increase (Decrease) in Stockholders' Equity
Stock-based compensation		3,574		3,574
Stock-based compensation (in shares)	1,722,125
Issuance of common stock, net of issuance costs	$ 1	41,679		41,680
Issuance of common stock, net of issuance costs (in shares)	7,479,476
Issuance of stock for business acquisition, net of issuance costs	$ 1	53,102		53,103
Issuance of stock for business acquisition, net of issuance costs (in shares)	5,471,804
Issuance of common stock related to debt conversion		1,058		1,058
Issuance of common stock related to debt conversion (in shares)	130,081
Estimated fair value of replacement equity awards		432		432
Contingent Value Rights payouts		1,000		$ 1,000
Contingent Value Rights payouts (in shares)	103,190			103,190
Tax withholding for stock-based compensation		(5)		$ (5)
Net loss			(58,289)	(58,289)
Ending balance at Jun. 30, 2021	$ 3	315,864	(178,299)	$ 137,568
Ending balance (in shares) at Jun. 30, 2021	27,490,412			27,490,412
Increase (Decrease) in Stockholders' Equity
Stock-based compensation		5,248		$ 5,248
Stock-based compensation (in shares)	408,689
Issuance of common stock, net of issuance costs	$ 1	11,652		11,653
Issuance of common stock, net of issuance costs (in shares)	8,490,784
Tax withholding for stock-based compensation		(8)		(8)
Issuance of common stock related to milestone payment		1,425		1,425
Issuance of common stock related to milestone payment (in shares)	2,188,940
Warrants issued with debt refinance		379		379
Net loss			(110,173)	(110,173)
Ending balance at Jun. 30, 2022	$ 4	$ 334,560	$ (288,472)	$ 46,092
Ending balance (in shares) at Jun. 30, 2022	38,578,825			38,578,825

Consolidated Statement of Sto_2

Consolidated Statement of Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Statement of Stockholders' Equity [Abstract]
Stock issued during period, value, new issues, issuance costs	$ 1,048	$ 3,371
Stock issued during period, value, acquisitions, issuance costs		$ 130

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating Activities
Net loss	$ (110,173)	$ (58,289)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation, amortization and accretion	10,251	9,201
Impairment expense	75,458	12,825
Shares issuance related to milestone payment	1,425	0
Stock-based compensation expense	5,248	3,574
(Gain) loss from contingent considerations	(1,760)	(4,459)
Amortization of senior debt (premium) discount	(126)	(44)
(Gain) loss on debt extinguishment	(193)	1,569
Inventory write-down	2,186	7,332
Gain on derivative warrant liability	(211)	0
Other noncash adjustments	4	38
Changes in allowance for bad debt	(69)	608
Changes in operating assets and liabilities:
Accounts receivable	6,533	1,544
Inventory	1,299	2,786
Prepaid expenses and other current assets	2,228	157
Accounts payable and other	(7,681)	(3,245)
Accrued liabilities	(13,292)	771
Other operating assets and liabilities, net	50	(332)
Net cash used in operating activities	(28,823)	(25,964)
Investing Activities
Contingent consideration payment	(3,178)	(683)
Cash received from acquisition	0	15,722
Cash payment for business acquisition	0	(15,520)
Cash payment for asset acquisition	0	(2,341)
Other investing activities	(70)	40
Net cash used in investing activities	(3,248)	(2,782)
Financing Activities
Net proceeds from issuance of stock	11,694	40,148
Payment made to fixed payment arrangement	(4,409)	(6,088)
Proceeds from short-term line of credit	152,236	51,206
Payments made on short-term line of credit	(156,357)	(53,979)
Payments made to borrowings	(16,101)	(968)
Proceeds from borrowings	15,000	0
Payment for debt issuance costs	(526)	0
Other financing activities	(7)	(5)
Net cash provided by financing activities	1,530	30,314
Net change in cash, cash equivalents, and restricted cash	(30,541)	1,568
Cash, cash equivalents and restricted cash at beginning of period	49,901	48,333
Cash, cash equivalents and restricted cash at end of period	19,360	49,901
Supplemental cash flow data
Cash paid for interest	3,148	1,249
Non-cash investing and financing activities:
Warrants issued	3,177	1,628
Other noncash investing and financing activities	$ 54
Issuance of common stock for note conversion		1,058
Contingent value rights payout		1,000
Issuance related to acquisition of Neos		53,103
Fair value of non-cash assets acquired		104,322
Fair value of liabilities assumed		88,700
Estimated fair value of replacement equity awards		$ 432

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
Cash and cash equivalents	$ 19,360	$ 49,649
Restricted cash	0	252
Total cash, cash equivalents and restricted cash	$ 19,360	$ 49,901	$ 48,333

Nature of Business and Financia

Nature of Business and Financial Condition	12 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Financial Condition	AYTU BIOPHARMA, INC. Notes to the Financial Statements 1. Nature of Business and Financial Condition Aytu BioPharma, Inc. (“Aytu,” the “Company” or “we”), is a pharmaceutical company focused on commercializing novel therapeutics and consumer health products and developing therapeutics for rare pediatric-onset or difficult-to-treat diseases. The Company operates through two business segments (i) the BioPharma segment, consisting of prescription pharmaceutical products (the “Rx Portfolio”) and (ii) the Consumer Health segment, which consists of various consumer healthcare products (the “Consumer Health Portfolio”). The Company also has two product candidates in development, AR101 (enzastaurin) for the treatment of vascular Ehlers-Danlos Syndrome (“VEDS”) and Healight (endotracheal ultraviolet light catheter) for the treatment of severe, difficult-to-treat respiratory infections. The Company was incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado and was re-incorporated as Aytu BioScience, Inc in the state of Delaware on June 8, 2015. Following the acquisition of Neos Therapeutics, Inc. (“Neos”) in March 2021, the Company changed its name to Aytu BioPharma, Inc. The BioPharma portfolio primarily consists of (i) Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (“ADHD”), (ii) Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency, and (iii) Karbinal ER, an extended-release antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions. The Consumer Health Portfolio consists of over twenty consumer health products competing in large healthcare categories, including diabetes management, pain management, digestive health, sexual and urological health, and general wellness, commercialized through direct-to-consumer and e-commerce marketing channels. The Company’s strategy is to continue building its portfolio of revenue-generating products, leveraging its commercial team’s expertise to build leading brands within large therapeutic markets, while also developing a therapeutic pipeline focused on rare pediatric-onset conditions and difficult-to-treat diseases. As of June 30, 2022, the Company had approximately $19.4 million of cash and cash equivalents. The Company’s operations have historically consumed cash and are expected to continue to consume cash. The Company incurred a net loss of approximately $110.2 million and $58.3 million during the years ended June 30, 2022 and 2021, respectively. The Company had an accumulated deficit of $288.5 million and $178.3 million as of June 30, 2022 and 2021, respectively. Cash used in operations was $28.8 million and $26.0 million during the years ended June 30, 2022 and 2021, respectively. In August 2022, the Company completed an underwritten public offering of (i) 21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 1,750,000 shares of its common stock, and (ii) accompanying warrants (the "Common Warrants") to purchase 23,255,814 shares of its common stock (the "Offering") resulting in gross and net proceeds of $10.0 million and $9.1 million, respectively, assuming none of the accompanying Common Warrants issued in the Offering are exercised. The pre-funded warrants were exercised in full in August 2022. The Company intends to use the net proceeds from the Offering for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome (“VEDS”), for growth of the company’s commercial business, and for working capital and general corporate purposes. As the Company does not have sufficient cash and cash equivalents as of June 30, 2022 to cover its cash needs for the twelve months following the filing date of this Annual Report on Form 10-K, there exists substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include adjustments that might be necessary if the Company is unable to continue as a going concern. Management plans to mitigate the conditions that raise substantial doubt about its ability to continue as a going concern are primarily focused on raising additional capital through public or private equity or debt offerings or monetizing assets in order to meet its obligations. Management believes that the Company has access to capital resources, however, the Company cannot provide any assurance that it will be able to raise additional capital, monetize assets or obtain new financing on commercially acceptable terms. If the Company is unable to secure additional capital, it may be required to curtail its operations or delay the execution of its business plan. Alternatively, any efforts by the Company to reduce its expenses may adversely impact its ability to sustain revenue-generating activities and delay the progress of its developmental product candidates or otherwise operate its business. As a result, there can be no assurance that the Company will be successful in implementing its plans to alleviate this substantial doubt about its ability to continue as a going concern.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Significant Accounting Policies	2. Summary of Significant Accounting Policies Principals of Consolidation . Basis of Presentation . Use of estimates . Prior Period Reclassification . Cash, Cash Equivalents and Restricted Cash . Accounts Receivable . Inventories . The Company periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If evidence exists that the net realizable value of inventory is lower than its cost, the difference is recognized as a loss in the period the impairment is identified. Going Concern Determination . Property and equipment . Furniture equipment two Leases . Fixed lease payments, or in substance fixed, are recognized over the expected term of the lease using the effective interest method. Variable lease payments are expensed as incurred. Fixed and variable lease expenses on operating leases are recognized within cost of goods sold and operating expenses in the Company’s consolidated statements of operations. ROU asset amortization and interest costs on financing leases are recorded within cost of goods sold and interest expense, respectively, in the Company’s consolidated statements of operations. The Company has elected to account for payments on short-term leases as lease expense on a straight-line basis over lease terms of 12 months or less. Operating leases are included in other liabilities in the Company’s consolidated balance sheets. Financing leases are included in property and equipment, net, current portion of long-term debt and long-term debt, net of current portion in the Company’s consolidated balance sheets. Fair Value of Financial Instruments Acquisitions . Revenue Recognition . BioPharma segment Net product sales for the BioPharma segment consist of sales of prescription pharmaceutical products under the Rx Portfolio, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx product revenue is recognized at the point in time that control of the product transfers to the customer in accordance with shipping terms (i.e., upon delivery), which is generally “free-on-board” destination when shipped domestically within the United States and “free-on-board” shipping point when shipped internationally consistent with the contractual terms. Rx product revenue is recognized net of consideration paid to the Company’s customers and other adjustments to the transaction price (known as “Gross to Net” adjustments). Estimating adjustments to the transaction price and applying the constraint on variable consideration requires the use of significant management judgment and other market data. Gross to Net adjustments include provisions for product returns, wholesaler distribution fees and chargebacks for discounted pricing to participating entities, managed care rebate programs, savings programs for patients covered under commercial payor plans and other deductions. Consumer Health segment The Consumer Health segment generates its revenue from sales of various consumer health products through direct-to-consumer marketing channels utilizing the Company's proprietary Beyond Human marketing and sales platform and on e-commerce platforms. Revenue is generally recognized “free-on-board” shipping point, as those are the agreed-upon contractual terms. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from a customer are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of sales. Customer Contract Costs . Concentration of Credit Risk . The Company maintains deposits in financial institutions in excess of federally insured limits. The Company periodically monitors the credit quality of the financial institutions with which it invests and believes that the Company is not exposed to significant credit risk due to the financial position of those institutions. The Company is also subject to credit risk from accounts receivable related to product sales. The Company’s customers, sometimes referred to as partners or customers, are primarily large wholesale distributors that resell the Company’s products to retailers. The loss of one or more of these large customers could have a material adverse effect on the Company’s business, operating results or financial condition. The Company does not charge interest or require collateral related to its accounts receivable. Credit terms are generally forty The following table presents customers that contributed more than 10% of gross revenue and accounts receivable : ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Percentage of gross revenue ​ Percentage of accounts receivable ​ ​ June 30, ​ ​ 2022 ​ 2021 ​ 2022 ​ 2021 Customer A ​ 41 % ​ 25 % ​ 52 % ​ 35 % Customer B ​ 20 % ​ 15 % ​ 25 % ​ 29 % Customer C ​ 18 % ​ 14 % ​ 18 % ​ 22 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Costs of Sales . Stock-Based Compensation . Restricted stock and restricted stock unit grants are valued based on the estimated grant date fair value of the Company’s common stock and recognized ratably over the requisite service period. Stock option grants are valued using the Black-Scholes option pricing model and compensation costs are recognized ratably over the period of service using the graded method. The Black-Scholes option pricing model requires the Company to estimate the expected term of the award, the expected volatility, the risk-free interest rate, and the expected dividends. The expected term is determined using the “simplified method,” which is the midpoint between the vesting date and the end of the contractual term. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for the expected term of the award. The Company doesn’t anticipate paying any dividends in the near future. Forfeitures are recognized as they occur. Research and Development Intangible Assets . Impairment of Long-lived Assets and Goodwill . ​ Goodwill is reviewed for impairment at least annually or whenever events or changes in circumstances, including a decline in the Company’s stock price, indicate that its carrying amount is less than its fair value. If qualitative factors, such as general economic conditions, the Company’s outlook and market performance of the Company’s industry forecasted financial performance indicate that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, the Company performs a quantitative analysis of fair value. The Company determines the fair value of a reporting unit utilizing a discounted cash flow model. Significant assumptions inherent in the valuation methodologies include, but are not limited to, prospective financial information, growth rates, terminal value, discount rates and comparable multiples from publicly traded companies in the Company’s industry. Contingent consideration . ​ Advertising Costs . Income Taxes . The Company recognizes the effect of income tax positions only if those positions are more likely than not of to be sustained upon an examination. The Company recognizes interest and penalties related to uncertain tax positions in Income tax (provision) benefit in the consolidated statements of operations. Debt issuance costs, discounts (premiums) . Segment information . Paragraph IV litigation costs . Business Combination and Contingent considerations . The consideration for our acquisitions and certain licensing agreements often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Management estimates the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. The Company revalues its contingent consideration obligations each reporting period using Monte Carlo simulation. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income. Net Loss Per Common Share . the years ended June 30, 2022 and 2021, the Company incurred a net loss and did not include common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive. The following table sets-forth securities excluded from the calculation of diluted earnings per share ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2022 2021 Warrant to purchase common stock (Note 17) ​ 8,688,576 1,279,057 Employee stock options (Note 16) ​ 80,377 109,588 Employee unvested restricted stock (Note 16) ​ 1,607,572 1,955,426 Employee unvested restricted stock units ​ (Note 16) ​ 170,000 ​ 78,318 Total ​ ​ ​ 10,546,525 3,422,389 ​ ​ Recently Adopted Accounting Pronouncements Simplifying the Accounting for Income Taxes. Simplifying the Accounting for Income Taxes Recent Accounting Pronouncements Not Yet Adopted Debt—Debt with Conversion and Other Options. Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40)— “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” Financial Instruments Credit Losses. ASU 2016-13, “Financial Instruments – Credit Losses” Financial Instruments – Credit Losses Financial Instruments – Credit Losses (topic 326) Troubled Debt Restructurings and Vintage Disclosures Reference Rate Reform. Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting Reference Rate Reform (Topic 848) Earnings Per Share. Earnings Per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on our consolidated financial statements and related disclosures. ​ ​ ​

Revenues from Contracts with Cu

Revenues from Contracts with Customers	12 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenues from Contracts with Customers	3. Revenues from Contracts with Customers The Company disaggregates its revenue into three product portfolios. The primary care portfolio is composed of ZolpiMist and Tuzistra. The pediatric portfolio is composed of Adzenys XR-ODT, Cotempla XR-ODT Poly-Vi-Flor, Tri-Vi-Flor, Karbinal ER and a generic Tussionex. The Consumer Health portfolio is composed of over twenty consumer health products competing in large healthcare categories. As part of the realization of post-acquisition synergies and product prioritization, the Company has implemented a portfolio rationalization plan whereby it discontinued or divested non-core products including Cefaclor, Flexichamber, Tussionex, Tuzistra XR, and Zolpimist, effectively eliminating the primary care portfolio. These products, collectively, contributed $2.1 million in net revenue and $0.6 million in gross loss during the year ended June 30, 2022 (see Note 8 – Goodwill and Other Intangible Assets). Revenues by Product Portfolio ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ 2022 2021 ​ ​ (In thousands) ADHD portfolio $ 42,855 $ 10,883 Pediatric portfolio ​ ​ 16,084 ​ ​ 12,437 Consumer Health portfolio ​ ​ 35,548 ​ ​ 32,954 Other ​ ​ 2,182 ​ ​ 9,358 Consolidated revenue $ 96,669 $ 65,632 ​ ​ Revenues by Geographic location. ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ 2022 2021 ​ ​ (In thousands) U.S. ​ $ 94,606 ​ $ 60,687 International ​ 2,063 ​ 4,945 Total net revenue ​ $ 96,669 ​ $ 65,632 ​ ​ ​

Acquisitions

Acquisitions	12 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions - Neos Acquisition	Neos Acquisition On The following table summarizes the fair value of assets acquired and liabilities assumed in the acquisition: ​ ​ ​ ​ ​ ​ March 19, 2021 ​ ​ (In thousands, except share and per-share) Considerations: ​ ​ ​ Fair Value of Aytu Common Stock ​ ​ ​ Total shares issued at close ​ 5,471,804 Fair value per share of Aytu common stock $ 9.73 Fair value of equity consideration transferred $ 53,241 Cash ​ ​ 15,383 Estimated fair value of replacement equity awards ​ ​ 432 Total consideration transferred $ 69,056 ​ ​ ​ ​ ​ ​ ​ March 19, 2021 ​ ​ (In thousands) Total consideration transferred $ 69,056 Recognized amounts of identified assets acquired and liabilities assumed ​ ​ ​ Cash and cash equivalents $ 15,722 Accounts receivable ​ ​ 24,696 Inventory ​ ​ 10,984 Prepaid expenses and other current assets ​ ​ 2,929 Operating leases right-to-use assets ​ ​ 3,515 Property, plant and equipment ​ ​ 5,519 Intangible assets ​ ​ 56,530 Other long-term assets ​ ​ 149 Accounts payable and accrued expenses ​ ​ (56,718) Short-term line of credit ​ ​ (10,707) Long-term debt, including current portion ​ ​ (17,678) Operating lease liabilities ​ ​ (3,515) Other long-term liabilities ​ ​ (82) Total identifiable net assets ​ 31,344 Goodwill $ 37,712 ​ The fair values of the identifiable intangible assets acquired were as follows; ​ ​ ​ ​ ​ ​ ​ March 19, 2021 ​ ​ (In thousands) Identified intangible assets acquired: ​ ​ ​ Developed technology right $ 30,200 Developed products technology ​ ​ 22,700 In-process R&D ​ ​ 2,600 RxConnect ​ ​ 630 Trade name ​ ​ 400 Total intangible assets acquired $ 56,530 ​ The fair value of the Neos trade name, in-process R&D and developed product technology, which is the proprietary technology for the development of Adzenys XR-ODT, Adzenys ER, Cotempla XR-ODT and generic Tussionex, were determined using the relief from royalty method. The fair value of the developed technology right, which is a proprietary modified-release drug delivery technology, was determined using multi-period excess earnings method. The fair value of RxConnect was determined using the cost to recreate method. The finite-lived intangible assets are being amortized over a range of 1 The following supplemental unaudited proforma financial information presents the Company’s results as if the Neos acquisition had occurred on July 1, 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ 2022 2021 ​ ​ ​ ​ Pro forma ​ ​ Unaudited Unaudited ​ ​ (In thousands) Total revenues, net ​ $ 96,669 ​ $ 98,085 Net loss ​ $ (110,173) ​ $ (74,710) ​ ​ A R101 Acquisition

Inventories

Inventories	12 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Inventories	5. Inventories Inventories consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2022 ​ 2021 ​ (In thousands) Raw materials $ 1,814 $ 2,269 Work in process ​ ​ 1,838 ​ ​ 3,346 Finished goods ​ 7,197 ​ 10,724 Inventory, net ​ $ 10,849 ​ $ 16,339 ​ ​ The Company incurred charges of $4.2 million and $7.3 million to reduce the carrying value of inventory to net realizable value during the years ended June 30, 2022 and 2021, respectively, primarily as a result of the discontinuance of non-core products.

Property and Equipment

Property and Equipment	12 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	6. Property and Equipment Property and equipment, net consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) Manufacturing equipment ​ $ 2,487 $ 3,070 Leasehold improvements 999 ​ 959 Office equipment, furniture and other 1,128 ​ 1,093 Lab equipment 832 ​ 832 Assets under construction — ​ 198 Property and equipment, gross ​ ​ 5,446 ​ ​ 6,152 Less accumulated depreciation and amortization ​ ​ (2,421) ​ ​ (1,012) Property and equipment, net $ 3,025 ​ $ 5,140 ​ ​ Depreciation expense was $1.6 million and $0.6 million for the years ended June 30, 2022 and 2021, respectively. During the year ended June 30, 2022 and 2021, the Company recognized a gain of $0.1 and a loss of $0.1 million on the disposal of equipment, respectively. During the year ended June 30, 2022, in connection with the decision to divest Tussionex, the Company recorded a $0.2 million impairment

Leases

Leases	12 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Leases	7. Leases The Company’s operating leases are for its offices, manufacturing facilities and equipment, and its finance leases are for equipment. These leases have original lease periods expiring between 2022 and 2027. Most leases include option provisions under which the parties may extend the lease term. Certain non-real estate leases also include options to purchase the leased property. The Company’s lease agreements generally do not contain any material residual value guarantees or material restrictive covenants. In connection with the Neos Acquisition, Aytu assumed an operating lease ROU asset and lease liability In the fiscal years ended June 30, 2021 and June 30, 2022, the Company entered into a lease agreements for which the Company recorded operating lease and lease lia3bilities ​ The components of lease expenses are as follows; ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ ​ ​ June 30, ​ ​ ​ 2022 2021 Statement of Operations Classification ​ ​ (In thousands) ​ ​ Lease cost: ​ ​ ​ ​ ​ ​ ​ ​ Operating lease cost ​ $ 1,299 ​ $ 476 Operating expenses Short-term lease cost ​ 152 ​ 109 Operating expenses Finance lease cost: ​ ​ ​ ​ ​ ​ ​ Amortization of leased assets ​ 73 ​ 21 Cost of sales Interest on lease liabilities ​ ​ 14 ​ ​ 6 ​ Other (expense), net Total net lease cost ​ $ 1,538 ​ $ 612 ​ ​ Supplemental balance sheet information related to leases is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, Balance Sheet Classification ​ ​ 2022 ​ 2021 ​ ​ ​ ​ (In thousands) ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ Operating lease assets ​ $ 3,271 ​ $ 3,563 Operating lease right-of-use asset Finance lease assets ​ ​ 256 ​ 329 Property and equipment, net Total leased assets ​ $ 3,527 ​ $ 3,892 ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ Current: ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ $ 1,227 ​ $ 940 ​ Other current liabilities Finance leases ​ ​ 96 ​ ​ 102 ​ Current portion of debt Non-current ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 2,090 ​ ​ 2,624 ​ Other liabilities Finance leases ​ ​ 84 ​ ​ 180 ​ Debt, net of current portion Total lease liabilities ​ $ 3,497 ​ $ 3,846 ​ ​ ​ ​ Remaining lease terms and discount rates used are as follows; ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2022 ​ 2021 ​ Weighted-Average Remaining Lease Term (years) ​ ​ ​ ​ ​ ​ ​ Operating lease assets ​ 2.63 ​ ​ 3.42 ​ Finance lease assets ​ 1.73 ​ ​ 2.72 ​ Weighted-Average Discount Rate ​ ​ ​ ​ ​ ​ Operating lease assets ​ 7.48 % ​ 6.62 % Finance lease assets ​ ​ 6.43 % ​ 6.41 % ​ ​ Supplemental cash flow information related to leases is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ 2022 2021 ​ ​ (In thousands) Cash flow classification of lease payments: ​ ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ $ 1,016 ​ $ 467 Operating cash flows from finance leases ​ $ 15 ​ $ 5 Financing cash flows from finance leases ​ $ 102 ​ $ 25 ​ ​ As of June 30, 2022, the maturities of the Company’s future minimum lease payments were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Finance ​ ​ (In thousands) 2023 ​ $ 1,436 ​ $ 105 2024 ​ ​ 1,378 ​ ​ 87 2025 ​ ​ 749 ​ ​ — 2026 ​ ​ 90 ​ ​ — 2027 ​ ​ 46 ​ ​ — Total lease payments ​ ​ 3,699 ​ ​ 192 Less: Imputed interest ​ ​ (382) ​ ​ (12) Lease liabilities ​ $ 3,317 ​ $ 180 ​ ​ ​ ​

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	8. Goodwill and Other Intangible Assets The carrying amount of goodwill by reportable segment and changes during the year ended June 30, 2022 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ BioPharma Consumer Health Consolidated ​ ​ (In thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance as of June 30, 2020 ​ $ 19,453 ​ $ 8,637 ​ $ 28,090 Goodwill acquired ​ ​ 37,712 ​ ​ — ​ ​ 37,712 Balance as of June 30, 2021 ​ ​ 57,165 ​ ​ 8,637 ​ ​ 65,802 Goodwill impairment ​ (57,165) ​ (8,637) ​ (65,802) Balance as of June 30, 2022 ​ $ — ​ $ — ​ $ — ​ ​ During the year ended June 30, 2022, the Company’s market capitalization significantly declined. The decline was considered a qualitative factor that led management to reassess whether an impairment had occurred. Management’s evaluation indicated that the goodwill related to its reporting units in both the BioPharma and Consumer Health segments were potentially impaired. The Company then performed a quantitative impairment test by calculating the fair value of the reporting unit and compared that amount to its carrying value. Significant assumptions inherent in the valuation methodologies include, but were not limited to prospective financial information, growth rates, terminal value, discount rates and comparable multiples from publicly traded companies in our industry. The decline in market capitalization was an indicator of increased risk thereby increasing the discount rates in the valuation models. The Company determined the fair value of the reporting unit utilizing the discounted cash flow model. Using Utilizing a risk adjusted weighted-average discount rate, the fair value of the reporting units was less than its carrying value. The Company recognized an impairment charge of $57.2 million in the BioPharma segment, associated with the Cerecor and Neos acquisition and a $8.6 million impairment charge in the Consumer Health segment related to the goodwill associated with the Innovus Acquisition. The following table provides the summary of the Company’s intangible assets as of June 30, 2022 and June 30, 2021, respectively. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology right ​ ​ 45,400 ​ ​ (7,667) ​ ​ (3,224) ​ ​ 34,509 12.33 Acquired technology right ​ ​ 30,200 ​ ​ (2,278) ​ ​ — ​ ​ 27,922 ​ 15.75 Acquired product distribution rights ​ 11,354 ​ (3,581) ​ (2,172) ​ 5,601 7.60 Other intangible assets ​ ​ 4,666 ​ ​ (3,004) ​ ​ (1,662) ​ ​ — ​ — ​ ​ ​ 91,620 ​ ​ (16,530) ​ ​ (7,058) ​ ​ 68,032 ​ 13.35 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ ​ 2,600 ​ ​ — ​ ​ — ​ ​ 2,600 ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ — ​ ​ 2,600 ​ ​ Total ​ $ 94,220 ​ $ (16,530) ​ $ (7,058) ​ $ 70,632 13.35 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Average ​ ​ Carrying ​ Accumulated ​ Net Carrying ​ Remaining ​ Amount Amortization Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology right ​ ​ 45,400 ​ ​ (4,160) ​ ​ 41,240 ​ 12.88 Acquired technology right ​ ​ 30,200 ​ ​ (501) ​ ​ 29,699 ​ 16.75 Acquired product distribution rights ​ ​ 11,354 ​ ​ (2,073) ​ ​ 9,281 ​ 8.57 Other intangible assets ​ ​ 4,666 ​ ​ (2,022) ​ ​ 2,644 ​ 3.05 ​ ​ ​ 91,620 ​ ​ (8,756) ​ ​ 82,864 ​ 13.47 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ 2,600 ​ — ​ 2,600 ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ 2,600 ​ ​ Total ​ $ 94,220 ​ $ (8,756) ​ $ 85,464 ​ 13.47 ​ ​ ​ The following table summarizes the estimated future amortization expense to be recognized over the next five years and periods thereafter: ​ ​ ​ ​ ​ ​ June 30, ​ ​ (In thousands) 2023 ​ $ 6,086 2024 ​ ​ 6,074 2025 ​ ​ 5,934 2026 ​ ​ 5,683 2027 ​ ​ 5,653 Thereafter ​ ​ 38,602 Total future amortization expense ​ $ 68,032 ​ ​ Product Technology Rights The acquired Product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisitions of Pediatric Portfolio in November 2019 and the Neos Acquisition in March 2021. Karbinal® ER. 20-year Poly-Vi-Flor and Tri-Vi-Flor. ADHD Portfolio. Developed Technology Right TRRP Technology. Product distribution rights and customer list In connection with the Innovus Acquisition, the Company obtained 35 products with a combination of over 300 registered trademarks and/or patent rights and customer lists. As of June 30, 2022, the customer list intangible asset was fully amortized. In-Process R&D IPR&D – NT0502. Other intangible assets Other intangible assets consist of customer lists, trade names and other technology and licenses. Certain of the Company’s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $7.8 million and $7.1 million during the years ended June 30, 2022 and 2021, respectively. During the year ended June 30, 2022, in connection with the decision to discontinue commercializing or divesting certain products within the BioPharma segment that have minimal revenue and gross margin contribution, the Company recorded $4.9 million impairment During the year ended June 31, 2021, the Company recorded $12.8 impairment expense in the BioPharma segment consisting of (1) $4.3 million in connection with the divestiture of Natesto and (2) $8.5 million for write-down of Tuzistra licensed asset.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Jun. 30, 2022
Accrued Liabilities, Current [Abstract]
Accrued Liabilities	9. Accrued liabilities Accrued liabilities consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) ​ ​ ​ ​ ​ ​ ​ Accrued savings offers ​ $ 12,711 ​ $ 20,148 Accrued program liabilities ​ ​ 9,468 ​ ​ 8,689 Return reserve ​ 5,770 ​ 6,367 Accrued compensation ​ ​ 4,765 ​ ​ 5,939 Accrued customer and product related fees ​ ​ 7,817 ​ ​ 12,346 Other accrued liabilities ​ ​ 3,656 ​ ​ 3,745 Total accrued liabilities ​ $ 44,187 ​ $ 57,234 ​ ​ Accrued customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions. ​ Other accrued liabilities consist of accrued license fees, professional fees, credit card liabilities, taxes payable, and samples expense, none of which individually represent greater than five percent .

Other Liabilities

Other Liabilities	12 Months Ended
	Jun. 30, 2022
Other Liabilities Disclosure [Abstract]
Other Liabilities	10. Other Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) ​ ​ ​ ​ ​ ​ ​ Contingent consideration ​ $ 396 ​ $ 12,057 Fixed payment arrangement ​ ​ 13,051 ​ ​ 9,458 Operating lease liabilities ​ 3,317 ​ 3,564 Contingent value rights ​ ​ 578 ​ ​ 1,395 Other ​ ​ 827 ​ ​ 355 Total other liabilities ​ ​ 18,169 ​ ​ 26,829 Less: current portion ​ ​ (5,359) ​ ​ (8,347) Total other liabilities, noncurrent ​ $ 12,810 ​ $ 18,482 ​ ​ Fixed payment arrangements. On June 21, 2021, the Company entered into a Waiver, Release and Consent pursuant to which the Company paid $2.8 million to the investor in early satisfaction of the fixed obligation. The Company agreed to pay the remaining fixed obligation of $3.0 million in six equal quarterly payments of $0.5 million each over six quarters beginning September 30, 2021. The Company accounted the Waiver, Release and Consent as a debt and remeasured the related liabilities using a discounted cash flow model. As of June 30, 2022, the fixed payment arrangement was $1.0 million. The Company recognized a $1.3 million loss on extinguishment of the fixed obligation for the year ended June 30, 2021. In addition, the Company acquired a Supply and Distribution Agreement with Tris (the “Karbinal Agreement”), under which the Company is granted the exclusive right to distribute and sell the product in the United States. The initial term of the Karbinal Agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales. The Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the first of which is triggered at $40.0 million of net revenues. On May 12, 2022, the Company entered into an agreement with Tris to terminate the License, Development, Manufacturing and Supply Agreement dated November 2, 2018 (the “License Agreement”). Pursuant to such termination, the Company agreed to pay Tris a total of approximately $6.0 million to $9.0 million, which reduced our total liability for minimum payments by approximately $8.0 million from the original License Agreement. The settlement payment will be paid in three installments from December 2022 through July 2024. As of June 30, 2022, the balance was $6.7 million. Contingent value rights. 30, 2022. As of June 30, 2022, up to $5.0 million of future milestone payments potentially remain. As of June 30, 2022 and June 30, 2021, the CVRs were revalued at $0.6 million and $1.4 million, respectively. During the years ended June 30, 2022 and 2021, the Company recognized a gain of $0.8 million and $3.2 million, respectively, in the consolidated statements of operations related to the changes in fair values of CVRs. Contingent consideration As of June 30, 2022, the Company’s contingent consideration liabilities consist primarily of obligations related to the Company’s 2020 acquisition of Innovus. In connection with the acquisition, the Company assumed a license agreement for patents and technology under which Innovus will pay a total milestone payment of $50,000 every other year beginning on July 1, 2021 for a total payment of $0.2 million. The fair value was based on a discounted value of the future contingent payment using a 26% discount rate based on the estimated risk that the milestones would be achieved. In addition, Innovus recognized approximately $0.2 million in product related contingent consideration. The fair value was based on a discounted value of the future contingent payment using a 30% discount rate based on the estimated risk that the milestones are achieved. As of June 30, 2022 and June 30, 2021, the contingent consideration balance were $0.4 million and $0.3 million, respectively. Prior to June 30, 2022, the Company’s contingent consideration liabilities included obligations under licensing arrangements for Tuzistra XR . Prior to June 30, 2022, the royalty payments related to licensing agreements with Magna Pharmaceuticals, Inc. (“Magna”) for ZolpiMist were being accounted for as contingent consideration and revalued at each reporting period. As a result of the discontinuation of commercializing ZolpiMist, the Company concluded that the royalty-based product milestone payments underlying the contingent consideration liability ceased to exist. In 2022, the Company reversed the remaining contingent consideration liabilities of $0.6 million and recorded the $50,000 payment due for termination of the Manga licensing agreements in other current liabilities. The Company recognized a $0.6 million gain from termination of the contingent consideration liability in the consolidated statements of operations for the year ended June 30, 2022. During the year ended June 30, 2022 and 2021, the Company recognized a net a loss of $0.5 million and $1.7 million, respectively, from the changes in fair values of contingent considerations. The total accretion expense related to these contingent considerations was approximately $0.1 million and $0.4 million during the year ended June 30, 2022 and 2021, respectively. Other.

Line of Credit

Line of Credit	12 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Line of Credit	11. Line of Credit Upon closing of the Neos Acquisition in March 2021, the Company assumed obligations under the secured credit agreement that Neos had entered into with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”) as agent for the lenders (the “Eclipse Loan Agreement”). Under the Eclipse Loan Agreement, Eclipse extended up to $25.0 million in secured revolving loans to Neos (the “Revolving Loans”), of which up to $2.5 million was available for short-term swingline loans, against 85% of eligible accounts receivable. The Revolving Loans thereunder accrued variable interest through maturity at the one-month Secure Overnight Financing Rate (“SOFR), plus 4.50%. The Eclipse Loan Agreement included an unused line fee of 0.50% of the average unused portion of the maximum revolving facility amount during the immediately preceding month. Interest is payable monthly in arrears. The original maturity date under the Eclipse Loan Agreement was May 11, 2022. In connection with the Avenue Capital Agreement, described in Note 12 Long Term Debt below, the Company entered into a Consent, Waiver and Second Amendment to Eclipse Loan Agreement, dated as of January 26, 2022 (together, the “Eclipse Second Amendment”). Pursuant to the Eclipse Second Amendment, Eclipse (i) consented to Aytu and certain of its subsidiaries joining as obligors to the Revolving Loans provided by the Eclipse Loan Agreement, (ii) consented to the Company entering into the Avenue Capital Agreement, (iii) extended the maturity date of the Eclipse Loan Agreement to January 26, 2025, (iv) removed the requirement for the Company to comply with the ongoing fixed charge coverage ratio financial covenant applicable to the borrowers under the Eclipse Loan Agreement, (v) consented to the first priority lien granted by Aytu in favor of the Avenue Capital Agent, (vi) reduced the maximum availability under the Revolving Loans from $25.0 million to $12.5 million minus a $3.5 million availability block, (vii) increased the availability block from $1.0 million to $3.5 million, (viii) consented to the full repayment under the Deerfield Facility, defined below, and (ix) made certain other modifications to conform to the Avenue Capital Agreement and to reflect the consummation of the transactions thereof, in each case subject to the terms and conditions of the Eclipse Second Amendment. The Company incurred $0.1 million in legal and other fees related to the Eclipse Second Amendment, all of which were recorded as deferred financing costs and are being amortized on a straight-line basis over the remaining term of the Eclipse Loan Agreement as interest expense. The unamortized cost of $0.1 million as of June 30, 2022 was included in other noncurrent assets in the condensed consolidated balance sheets. In the event that, for any reason, all or any portion of the Eclipse Loan Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i) 2.0% of the Revolving Loans commitment if such event occurs on or before January 26, 2023, (ii) 1.0% of the Revolving Loans commitment if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) 0.5% of the Revolving Loans commitment if such event occurs after January 26, 2024 but on or before January 26, 2025. The Company may permanently terminate the Eclipse Loan Agreement with at least five The Eclipse Loan Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Company’s obligations under the Eclipse Loan Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of June 30, 2022, the Company was in compliance with the covenants under the Eclipse Loan Agreement as amended. The Company’s obligations under the Eclipse Loan Agreement are secured by substantially all of the Company’s assets, with a first priority lien in favor of Eclipse on the ABL Priority Collateral, and a second priority lien in favor of Eclipse on the Term Loan Priority Collateral, as each is defined in the Replacement Term Loan Intercreditor Agreement, as defined in the Eclipse Loan Agreement, as amended by the Eclipse Second Amendment. Total interest expense on the Revolving Loans, including amortization of deferred financing costs, was $0.4 million for the year ended June 30, 2022. Interest expense was $0.2 for the period beginning March 19, 2021, the date the Neos Acquisition was closed, through June 30, 2021. As of June 30, 2022 and 2021, the outstanding Revolving Loans under the Eclipse Loan Agreement, as amended, were $3.8 million and $7.9 million, respectively. Unused line of credit amount as of June 30, 2022 was $0.3 million.

Long-term Debt

Long-term Debt	12 Months Ended
	Jun. 30, 2022
Long-term Debt
Long-term Debt	12. Long-term Debt Deerfield Debt. The Company evaluated and determined that the fair value of the remaining outstanding debt was $17.4 million as of the March 19, 2021 acquisition date. Accordingly, the Company recorded a premium of $0.8 million, which was the difference between carrying amount and the fair value of the debt and was being amortized into interest expense using the effective interest method over the remaining term of the debt. On January 26, 2022, the Company repaid the remaining principal outstanding in full, plus exit fees and accrued interest under the Deerfield Facility. The Company recognized a gain of $0.2 million during the year ended June 30, 2022 related to the extinguishment of the Deerfield Facility. Total interest expense on the facility, net of premium amortization, was $0.8 million for the period from July 1, 2021 through full repayment on January 26, 2022. Avenue Capital Loan: Pursuant to the Avenue Capital Agreement, the Company will make interest only payments for the first 18 months following the Closing Date (“Interest-only Period”). The Interest-only Period could be extended automatically without any action by any party for six months provided as of the last day of the Interest-only Period then in effect, the Company received, prior to June 15, 2023, a specified amount of net proceeds from the sale and issuance of its equity securities (“Interest-only Milestone 1”). The Interest-only Period could further be extended automatically without any action by any party for an additional six months provided, the Company has achieved, prior to December 31, 2023, (i) Interest-only Milestone 1 and (ii) a specified amount of trailing 12 months revenue as of the date of determination. In the event the Company prepays the outstanding principal prior to the maturity date, the Company will pay Avenue Capital a fee equal to (i) 3.0% of the loan if such event occurs on or before January 26, 2023, (ii) 2.0% of the loan if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) 1.0% of the loan if such event occurs after January 26, 2024 but before January 26, 2025. In addition, upon the payment in full of the obligations, the Company shall pay to Avenue Capital a fee in the amount of $0.6 million (“Final Payment”). The Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount. The Company’s obligations under Avenue Capital Agreement are secured by substantially all of the Company’s assets, with a first priority lien in favor of the Avenue Capital Agent on the Term Loan Priority Collateral, and a second priority lien in favor of the Avenue Capital Agent on the ABL Priority Collateral, as each is defined in the Intercreditor Agreement, as defined in the Avenue Capital Agreement. The Avenue Capital Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of the Avenue Capital Lenders. A failure to comply with these covenants could permit the Avenue Capital Lenders to declare the Company’s obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of June 30, 2022, the Company was in compliance with the covenants under the Avenue Capital Agreement. On January 26, 2022 (“Issuance Date”), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $1.21 per share (the “Avenue Capital Warrants”). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $1.21 prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on January 31, 2027. At inception and through the reclassification to equity on March 7, 2022, the Company accounted for the Avenue Capital Warrants as a liability as the number of warrants was not fixed at the Issuance Date. The fair value of the Avenue Capital Warrants was $0.6 million on January 26, 2022, with the corresponding debit being recorded as debt discount. On March 7, 2022, the Company closed on an equity offering of shares of common stock and warrants, as described in Note 15 – Stockholders Equity, at an offering price of $1.25 per share. As this offering precludes the Company from pursuing any equity financing prior to July 7, 2022 and the effective price of the March 7, 2022 offering was more than the exercise price of the Avenue Capital Warrants, the number of shares of common stock issuable upon exercise of the Avenue Capital Warrants were set to 867,769 at an exercise price of $1.21. As a result, on March 7, 2022, the Company reclassified the Avenue Capital Warrants from a liability to equity and recorded the $0.4 million fair value as additional paid in capital in stockholders’ equity in the Company’s financial statements. In addition to the debt discounts discussed above, the Company also incurred $0.4 million loan origination, legal and other fees. The debt discount and issuance costs are being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 16.59%. Total interest expense on the Avenue Capital loan, including debt discount amortization, was $0.9 million for the year ended June 30, 2022 Long-term debt consists of the following; ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2022 ​ ​ (In thousands) Long-term debt, due on January 26, 2025 ​ $ 15,000 Long-term, final payment fee ​ ​ 638 Unamortized discount and issuance costs ​ ​ (1,443) Financing leases, maturing through May 2024 ​ ​ 180 Total debt ​ ​ 14,375 Less: current portion ​ ​ (96) Non-current portion of debt ​ $ 14,279 ​ Future principal payments of long-term debt, including financing leases, are as follows; ​ ​ ​ ​ ​ ​ June 30, ​ ​ (In thousands) 2023 ​ $ 96 2024 ​ ​ 8,418 2025 ​ ​ 7,304 Future principal payments ​ ​ 15,818 Less unamortized discount and issuance costs ​ ​ (1,443) Less current portion ​ ​ (96) Non-current portion of debt ​ $ 14,279 ​

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	13. Fair Value Measurements We determine the fair value of financial and non-financial assets using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows: Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities; Level 2: Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and Level 3: Unobservable inputs that are supported by little or no market activity. The Company’s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, warrant derivative liability contingent consideration liabilities, and short-term and long-term debt. The carrying amounts of certain short-term financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Short-term and long-term debt are reported at their amortized costs on our consolidated balance sheets. The remaining financial instruments are reported on our consolidated balance sheets at amounts that approximate current fair values. The Company’s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented. Recurring Fair Value Measurement The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2022 and 2021, by level within the fair value hierarchy: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at June 30, 2022 ​ Fair Value at June 30, ​ ​ ​ ​ ​ 2022 (Level 1) (Level 2) (Level 3) ​ ​ (In thousands) Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 19,360 ​ $ 19,360 ​ $ — ​ $ — Total ​ $ 19,360 $ 19,360 $ — ​ $ — Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration $ 396 $ — $ — $ 396 CVR liability ​ 578 ​ — ​ — ​ 578 Warrant ​ ​ — ​ — ​ — ​ — Total ​ $ 974 $ — $ — ​ $ 974 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at June 30, 2021 ​ Fair Value at June 30, ​ ​ ​ ​ ​ 2021 (Level 1) (Level 2) (Level 3) ​ (In thousands) Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 49,649 ​ $ 49,649 ​ $ — ​ $ — Total ​ $ 49,649 $ 49,649 $ — ​ $ — Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration ​ $ 12,057 $ — $ — $ 12,057 CVR liability ​ ​ 1,395 ​ — ​ — ​ 1,395 Total ​ $ 13,452 $ — $ — ​ $ 13,452 ​ ​ Non-Recurring Fair Value Measurement The following able represents Company’s financial assets and liabilities that were accounted for at fair value on a non-recurring basis as of June 30, 2022 and 2021, by level within the fair value hierarchy: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at June 30, 2022 ​ Fair Value at June 30, ​ ​ ​ ​ ​ 2022 (Level 1) (Level 2) (Level 3) ​ ​ (In thousands) Non-recurring ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fixed payment arrangements ​ $ 13,051 ​ $ — ​ $ — ​ $ 13,051 Total ​ $ 13,051 $ — $ — ​ $ 13,051 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at June 30, 2021 ​ Fair Value at June 30, ​ ​ ​ ​ ​ 2021 (Level 1) (Level 2) (Level 3) ​ ​ (In thousands) Non-recurring ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fixed payment arrangements ​ $ 9,458 ​ $ — ​ $ — ​ $ 9,458 Total ​ $ 9,458 $ — $ — ​ $ 9,458 ​ ​ Summary of Level 3 Input Changes The following table sets forth a summary of changes to those fair value measures using Level 3 inputs for the year ended June 30, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CVR Contingent Fixed Payment ​ ​ Warrant ​ ​ Liability ​ Consideration ​ Arrangements ​ ​ Liability ​ ​ (In thousands) Balance as of June 30, 2021 $ 1,395 ​ $ 12,057 $ 9,458 ​ $ — Included in earnings ​ (817) ​ ​ 604 ​ 1,148 ​ ​ (211) Purchases, issues, sales and settlements: ​ ​ ​ ​ ​ ​ ​ Issues — ​ — 7,645 ​ 590 Settlements * — ​ (12,265) (5,200) ​ (379) Balance as of June 30, 2022 $ 578 ​ $ 396 $ 13,051 ​ $ — * Including $9.1 million reversal of contingent consideration liabilities see Note 10 Other Liabilities and $0.4 million liability warrants reclassified to equity Level 3 Inputs Changes in the fair value of contingent liabilities in subsequent periods are recorded as a loss (gain) in the statements of operations. Significant assumptions used in valuing the CVRs were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ 2022 ​ 2021 Leveraged Beta 0.85 ​ 0.91 ​ Market risk premium ​ 6.22 % ​ 6.00 % Risk-free interest rate ​ 2.86 % ​ 0.36 % Discount ​ 20.50 % ​ 13.00 % Company specific discount 10.00 % 5.00 % ​ ​ Significant assumptions used in valuing ​ ​ ​ ​ ​ ​ ​ January 26, ​ 2022 Expected volatility 56.75 % Equivalent term (years) ​ 5.00 ​ Risk-free rate ​ 1.66 % Dividend yield ​ 0.00 % ​ ​ The fixed payment arrangements are recognized at their amortized cost basis using market appropriate discount rates and are accreted up to their ultimate face value over time. Significant assumptions used in valuing the Fixed Payment Arrangements were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ 2022 2021 Discount rate - minimum 10.0 % 10.0 % Discount rate - maximum ​ 15.4 % ​ 12.4 % ​ ​ ​

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	14. Income Taxes The provision for income taxes consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) Current: ​ ​ ​ ​ ​ ​ Federal ​ $ — ​ $ — State ​ 7 ​ 16 Total current tax expense ​ 7 ​ 16 Deferred: ​ ​ ​ ​ Federal ​ (91) ​ 200 State ​ (26) ​ 43 Total deferred tax expense ​ (117) ​ 243 Provision for income taxes ​ $ (110) ​ $ 259 ​ ​ Income tax benefit resulting from applying statutory rates in jurisdictions in which the Company is taxed (Federal and various states) differs from the income tax provision (benefit) in the financial statements. Reconciliation of the U.S. federal statutory income tax rates to our effective tax rate is as follows. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2022 ​ ​ 2021 ​ ​ (In thousands) Tax at statutory rate ​ $ (23,159) ​ (21.00) % ​ $ (12,185) ​ (21.00) % State income taxes, net of federal benefit ​ ​ 601 ​ 0.55 % ​ ​ (2,461) ​ (4.24) % Permanent difference ​ ​ — ​ — % ​ ​ — ​ — % Stock based compensation ​ ​ 273 ​ 0.27 % ​ ​ 43 ​ 0.07 % Contingent consideration ​ ​ (155) ​ (0.14) % ​ ​ (667) ​ (1.15) % 162(m) limitation ​ ​ 76 ​ 0.08 % ​ ​ 235 ​ 0.40 % Goodwill impairment ​ ​ 9,733 ​ 8.83 % ​ ​ — ​ — % Transaction costs ​ ​ — ​ — % ​ ​ 160 ​ 0.28 % Change in tax rate ​ ​ — ​ — % ​ ​ — ​ — % Remeasurement of deferred taxes ​ ​ — ​ — % ​ ​ — ​ — % Effect of phased-in tax rate ​ ​ — ​ — % ​ ​ — ​ — % Loss on debt extinguishment and interest expense ​ ​ — ​ — % ​ ​ — ​ — % Change in valuation allowance ​ ​ 12,472 ​ 11.31 % ​ ​ 14,483 ​ 24.96 % Derivative income ​ ​ — ​ — % ​ ​ — ​ — % Other ​ ​ 49 ​ 0.01 % ​ ​ 651 ​ 1.13 % Net income tax provision (benefit) ​ $ (110) ​ (0.09) % ​ $ 259 ​ 0.45 % ​ ​ Deferred income taxes arise from temporary differences in the recognition of certain items for income tax and financial reporting purposes. The approximate tax effects of significant temporary differences which comprise the deferred tax assets and liabilities are as follows for the respective periods: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) Deferred tax assets: ​ ​ ​ ​ ​ ​ Net operating loss carry forward ​ $ 114,443 ​ $ 106,712 Accrued Rebates ​ ​ 5,944 ​ ​ 8,412 Share-based compensation ​ 2,773 ​ 2,330 Accrued expenses ​ ​ 817 ​ ​ 1,507 R&D credits ​ 2,423 ​ 2,115 Interest ​ ​ 2,975 ​ ​ 2,064 Inventory ​ 1,177 ​ 1,704 Lease liability ​ 799 ​ 1,031 Other ​ ​ 1,301 ​ ​ 1,526 Total deferred tax assets ​ ​ 132,652 ​ ​ 127,401 Less: valuation allowance ​ ​ (128,966) ​ ​ (116,494) Deferred tax assets, net of valuation allowance ​ ​ 3,686 ​ ​ 10,907 Deferred tax liabilities: ​ ​ ​ ​ ​ ​ Intangibles ​ (2,717) ​ (9,396) ROU asset ​ (308) ​ (1,009) Fixed assets ​ ​ (788) ​ ​ (745) Total deferred tax liabilities ​ ​ (3,813) ​ ​ (11,150) Net deferred tax liabilities ​ $ (127) ​ $ (243) ​ ​ In 2022, the impairment of goodwill decreased net deferred tax liabilities by $0.1 million resulting in an income tax benefit of $0.1 million. As of June 30, 2022, the Company had $0.1 million deferred tax liabilities included in other long-term liabilities in the consolidated balance sheet. The Company has recorded a valuation allowance of $129.0 million and $116.5 million at June 30, 2022 and 2021, respectively, to reserve its net deferred tax assets. The change in valuation allowance is due to the change in inventory of deferred items exclusive of indefinite lived deferred tax liabilities which cannot be fully offset with existing attributes. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, carry back opportunities and tax planning strategies in making the assessment. The Company believes it is more likely than not it will realize the benefits of these deductible differences, net of the valuation allowance provided. The Company had federal net operating losses of approximately $503.2 million and $466.7 million as of June 30, 2022, and June 30, 2021, respectively that, subject to limitation, may be available in future tax years to offset taxable income. Of the available federal net operating losses, approximately $171.5 million can be carried forward indefinitely while the remaining balance will begin to expire in 2024. As of June 30, 2022, the Company had research and development credits of $3.0 million, which begin to expire in 2024. The available state net operating losses, if not utilized to offset taxable Income in future periods, will begin to expire in 2025 through 2039. Under the provisions of the Internal Revenue Code, substantial changes in the Company’s ownership may result in limitations on the amount of NOL carryforwards that can be utilized in future years. Net operating loss carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by statute. The amount subject to disallowance is limited to the NOL utilized. Accordingly, the Company may be subject to examination for prior NOLs generated as such NOLs are utilized. As of June 30, 2022, the Company had various state NOL carryforwards. The determination of the state NOL carryforwards is dependent on apportionment percentages and state laws that can change from year to year and impact the amount of such carryforwards. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. The Company has no accrued interest related to its uncertain tax positions as they all relate to timing differences that would adjust the Company’s net operating loss carryforward, interest expense carryover or research and development credit carryover and therefore do not require recognition. As a result of these timing differences, at June 30, 2022 and 2021, the Company had gross unrecognized tax benefits related to uncertain tax positions of $9.8 million and $11.5 million, respectively. Changes in unrecognized benefits in any given year are recorded as a component of deferred tax expense. A tabular roll-forward of the Company’s gross unrecognized tax benefits is below. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) Beginning balance ​ $ 11,537 ​ $ — Increase resulting from prior period tax positions ​ — ​ 12,017 Increase resulting from current period tax positions ​ ​ — ​ ​ 2 Decrease resulting from current period tax positions ​ (1,704) ​ (482) Ending balance ​ $ 9,833 ​ $ 11,537 ​ ​ The change in the Company’s gross unrecognized tax benefits relates to the acquisition of Neos, whereby historic tax positions of Neos were inherited in the acquisition. Additionally, Neos pre-acquisition tax years are subject to the same general statute of limitations, resulting in its tax years back to 2004 being subject to examination.

Stockholders Equity

Stockholders Equity	12 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Stockholders Equity	15. Stockholders Equity The Company has 200.0 million shares of common stock authorized with a par value of $0.0001 per share and 50.0 million shares of preferred stock authorized with a par value of $0.0001 per share. As of June 30, 2022 and June 30, 2021, the Company had 38,578,825 and 27,490,412 common shares issued outstanding Included in the common stock outstanding are 1,707,730 shares of unvested restricted stock issued to executives, directors, and employees. On June 8, 2020, the Company filed a shelf registration statement (the “2020 Shelf”), which was declared effective by the SEC on June 17, 2021, covering up to $100.0 million of its common stock, preferred stock, debt securities, warrants, rights, and units. As of June 30, 2022, approximately $43.0 million remains available under the 2020 Shelf. On June 4, 2021, the Company entered into an agreement with an agent for the sale of up to $30.0 million of its common stock from time to time in “at-the-market” offerings under the 2020 Shelf (the “ATM Sales Agreement”). During the year ended June 30, 2022, the Company issued 2,430,784 shares of common stock under the ATM Sales Agreement, with total gross proceeds of approximately $5.1 million before deducting underwriting discounts, commissions, and other offering expenses of $0.2 million. As of June 30, 2022, approximately $12.2 million of the Company’s common stock remained available to be sold pursuant to the ATM Sales Agreement. On September 28, 2021, the Company filed a shelf registration statement (the “2021 Shelf”), which was declared effective by the SEC on October 7, 2021, covering up to $100.0 million of its common stock, preferred stock, debt securities, warrants, rights, and units. As of June 30, 2022, approximately $92.4 million remain available under the 2021 Shelf. On March 7, 2022, the Company closed on an underwritten public offering utilizing the 2021 Shelf, pursuant to which, the Company sold, (i) 3,030,000 shares of the Company’s common stock, (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 3,030,000 shares of common stock, and (iii) common stock purchase warrants (the “Common Warrants”) to purchase up to 6,666,000 shares of common stock (the “March 2022 Offering”). The shares of common stock and the Pre-Funded Warrants were each sold in combination with corresponding Common Warrants, with one Common Warrant to purchase 1.1 shares of common stock for each share of common stock or each Pre-Funded Warrant sold. The Pre-Funded Warrants have an exercise price of $0.0001 per share of common stock and were exercised in full in April 2022. The Common Warrants have an exercise price of $1.30 per share of common stock and are exercisable six months On January 26, 2022, as consideration for entering into the Avenue Capital Agreement, the Company issued the Avenue Capital Warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $1.21 per share. The Avenue Capital Warrants are immediately exercisable and expire on January 31, 2027. On March 7, 2022, the Company closed on an equity offering of shares of common stock and warrants, as described above, at an offering price of $1.25 per share. As this offering precluded the Company from pursuing any equity financing prior to July 7, 2022 and the effective price of the March 7, 2022 offering was more than the exercise price of the Avenue Capital Warrants, the number of common stock issuable upon exercise of the Avenue Capital Warrants were set to 867,769 shares at an exercise price of $1.21. As a result, on March 7, 2022, the Company reclassified the Avenue Capital Warrants from a liability to equity and recorded the $0.4 million fair value as additional paid in capital in stockholders’ equity in the Company’s financial statements (see Note 12 – Long-term Debt and Note 13 – Fair Value Considerations).

Equity Incentive Plans

Equity Incentive Plans	12 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Equity Incentive Plans	16. Equity Incentive Plans Aytu 2015 Plan. Neos 2015 Plan. 1 Stock Options Stock option activity is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average ​ Contractual ​ ​ Options ​ Exercise Price ​ Life in Years Outstanding June 30, 2021 109,588 ​ $ 14.52 8.07 Forfeited/Cancelled (15,569) ​ ​ 7.98 Expired (13,642) ​ ​ 9.65 Outstanding at June 30, 2022 80,377 ​ $ 16.61 7.77 ​ ​ ​ ​ ​ ​ ​ ​ Exercisable at June 30, 2022 54,649 ​ $ 20.58 7.77 ​ The following table details the options outstanding at June 30, 2022 by range of exercise prices: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Remaining ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ Contractual ​ ​ ​ ​ ​ Range of ​ Number of ​ Average ​ Life of ​ Number of ​ Weighted Exercise ​ Options ​ Exercise ​ Options ​ Options ​ Average Prices ​ Outstanding ​ Price ​ Outstanding ​ Exercisable ​ Exercise Price $ 6.2 - 9.70 38,998 ​ $ 6.44 7.65 19,882 ​ $ 6.50 $ 9.80 - 14.70 41,225 ​ $ 14.13 7.90 34,613 ​ $ 14.28 $ 2,800.00 - 4,200.00 154 ​ $ 3,255.06 3.80 154 ​ $ 3,255.06 ​ ​ 80,377 ​ $ 16.61 7.77 54,649 ​ $ 20.58 ​ No stock options were granted during the year ended June 30, 2022. The weighted-average grant date fair value of options granted during the years ended June 30, 2022 and June 30, 2021 was $0 and $3.81, respectively. As of June 30, 2022, there was $0.2 million of total unrecognized compensation cost adjusted for estimated forfeitures, related to non-vested stock options granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.6 years. Restricted Stock During the year ended June 30, 2022, the Company granted a total of 295,000 shares of restricted stock, with certain accelerated vesting conditions, to members of its management team pursuant to the Aytu 2015 Plan, of which 1/3 vest on the grant date and 1/12 on the first day of each quarter thereafter , subject to continuing employment with the Company through each vesting date. These restricted stock grants have a grant date fair value ranging from $2.65 per-share to $4.02 per-share. Restricted stock activity under the Aytu 2015 Plan is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2021 1,955,268 ​ $ 7.83 Granted 295,000 ​ ​ 3.67 Vested (642,696) ​ ​ 6.81 Unvested at June 30, 2022 1,607,572 ​ $ 7.47 ​ As of June 30, 2022, there was $9.6 million of total unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested restricted stock granted under the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.7 years. The total fair value of restricted stock vested during the year ended June 30, 2022 was $1.6 million. The Company previously issued 158 shares of restricted stock outside of the Aytu 2015 Plan, which vest in July 2026. On January 17, 2022, the Company granted 100,000 shares of restricted stock to team outside of the Aytu 2015 Plan, of which 1/3 vest on January 17, 2023 and 1/12 each quarter thereafter , subject to continuing employment with the Company through each vesting date until January 17, 2025. This restricted stock grant has a grant date fair value of $1.35 per-share. As of June 30, 2022, total Restricted Stock Units The year ended June 30, 2022, the Company granted a total of 170,000 shares of restricted stock units (“RSUs”), to pursuant team to the Aytu 2015 Plan, of which 1/3 1/12 on the first day of each quarter subject to continuing employment with the Company through each vesting date. $1.86 per-share. RSUs activity is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2021 78,318 ​ $ 7.20 Granted ​ 170,000 ​ ​ 1.29 Vested (15,396) ​ ​ 6.20 Forfeited ​ (62,922) ​ ​ 7.44 Unvested at June 30, 2022 170,000 ​ $ 1.29 ​ As of June 30, 2022, there was $0.2 million of total unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested RSUs granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.6 years. The total fair value of RSUs vested during the year ended June 30, 2022 was $0.1 million. Stock-based compensation expense related to the fair value of stock options and restricted stock and RSUs was included in the statements of operations as set forth in the below table: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ ​ 2022 2021 ​ ​ (In thousands) Cost of sales ​ $ 31 ​ $ 16 Research and development ​ ​ 536 ​ ​ 68 Selling and marketing ​ ​ 24 ​ ​ 27 General and Administrative ​ 4,657 ​ 3,463 Total stock-based compensation expense ​ $ 5,248 ​ $ 3,574 ​

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Jun. 30, 2022
Retirement Benefits [Abstract]
Employee Benefit Plan	18. Employee Benefit Plan Subsequent to the merger with Neos, Aytu has two 401(k) plans the (“Neos Plan”) and the (“Aytu Plan’) both plans allow participants to contribute a portion of their salary, subject to eligibility requirements and annual IRS limits. The Neos Plan matches 100% of the first 3% contributed by employees and matches 50% on the next 4% and 5% contributed by the employees. The Company’s match for the Neos Plan was approximately $0.4 million and $0.1 million for the years ended June 30, 2022 and 2021, respectively. The Aytu Plan matches 50% of the first 6% contributed to the plan by employees. The Company’s match for the Aytu Plan was approximately $0.2 million and $0.2 million during the years ended June 30, 2022 and 2021, respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	19. Commitments and Contingencies Pediatric Portfolio Fixed Payments and Product Milestone The Company assumed two fixed, periodic payment obligations to an investor (the “Fixed Obligation”). Under the first fixed obligation, the Company was to pay monthly payment of $0.1 million beginning November 1, 2019 through January 2021, with a balloon payment of $15.0 million that was to be due in January 2021 (“Balloon Payment Obligation”). A second fixed obligation requires the Company pay a minimum of $0.1 million monthly through February 2026, except for $0.2 million paid in January 2020. On May 29, 2020, the Company entered into an Early Payment Agreement and Escrow Instruction (the “Early Payment Agreement”) pursuant to which the Company agreed to pay $15.0 million to the investor in satisfaction of the Balloon Payment Obligation. The parties to the Early Payment Agreement acknowledged and agreed that the remaining fixed payments other than the Balloon Payment Obligation remained due and payable pursuant to the terms of the Agreement, and that nothing in the Early Payment Agreement alters, amends, or waives any provisions or obligations in the Waiver or the Investor agreement other than as expressly set forth therein. The first fixed obligation was fully paid as of January 2021. On June 21, 2021, the Company entered into a Waiver, Release and Consent pursuant to which the Company paid $2.8 million to the investor in satisfaction of the second fixed obligation. The company agreed to pay the remaining fixed obligation of $3.0 million in six equal quarterly payments of $0.5 million over the next six quarters commencing September 30, 2021. In addition, the Company acquired a Supply and Distribution Agreement with Tris (the “Karbinal Agreement”), under which the Company is granted the exclusive right to distribute and sell the product in the United States. The initial term of the Karbinal Agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales. The Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the first of which is triggered at $40.0 million of net revenues. Prior to June 30, 2022, the Company’s contingent consideration liabilities included obligations under licensing arrangements for Tuzistra XR . Product Contingent Liability In February 2015, Innovus acquired Novalere, which included the rights associated with distributing FlutiCare. As part of the Merger, Innovus is obligated to make five additional payments of $0.5 million when certain levels of FlutiCare sales are achieved. Pursuant to the UIRD Agreement, Innovus will pay to UIRD a total milestone payment of $50,000 every other year beginning on July 1, 2021 for a total payment of $0.2 million. The discounted value as of June 30, 2022, was approximately $0.1 million. The first milestone cash payment of $50,000 was made in July 2021. Rumpus Earn Out Payments On April 12, 2021, the Company acquired substantially all of the assets of Rumpus, pursuant to which the Company acquired certain rights and other assets, including key commercial global licenses with Denovo Biopharma LLC (“Denovo”) and Johns Hopkins University (“JHU”), relating to AR101. Upon the achievement of certain regulatory and commercial milestones, up to $67.5 million in earn-out payments, which are payable in cash or shares of common stock, generally at the Company’s option, are payable to Rumpus. Under the license agreement with Denovo, the Company assumed the responsibility for paying annual maintenance fees of $25,000, a license option fee of $0.6 million payable in April 2022, and upon the achievement of certain regulatory and commercial milestones, up to $101.7 million, and escalating royalties based on net product sales ranging in percentage from the low teens to the high teens. Finally, under the license agreement with Johns Hopkins, the Company assumed the responsibility for paying minimum annual royalties escalating from $5,000 to $20,000 beginning in calendar year 2022, royalties of 3.0% of net product sales, and upon the achievement of certain regulatory and commercial milestones, up to $1.6 million. During the year ended June 30, 2022, AR101 received Orphan Drug Designation (“ODD”) and Fast Track designation from the FDA, resulting in total milestone payments of $4.0 million, which were paid in 2,188,940 shares of common stock and $2.6 million in cash.

License Agreements

License Agreements	12 Months Ended
	Jun. 30, 2022
License Agreements [Abstract]
Licensing Agreements	20. License Agreements Healight In April 2020, the Company entered into a licensing agreement with Cedars-Sinai Medical Center to secure worldwide rights to various potential esophageal and nasopharyngeal uses of Healight, an investigational medical device platform technology. The agreement with Cedars-Sinai grants the Company a license to all patent and development related technology rights for the intra-corporeal therapeutic use of ultraviolet light in the field of endotracheal and nasopharyngeal applications. The term of the agreement is on a country-by-country basis and will expire on the latest of the date upon which the last to expire valid claim shall expire, ten years after the first bona fide commercial sale of such licensed product in a country, or the expiration of any market exclusivity period granted by a regulatory agency. Pursuant to the terms of the agreement, the Company paid an initial $0.3 million license fee and approximately $0.1 million in earlier patent prosecution fees. NeuRx In October 2018, Neos entered into an Exclusive License Agreement (“NeuRx License”) with NeuRx Pharmaceuticals LLC (“NeuRx”), pursuant to which NeuRx granted Neos an exclusive, worldwide, royalty-bearing license to research, develop, manufacture, and commercialize certain pharmaceutical products containing NeuRx’s proprietary compound designated as NRX-101, referred to by Neos as NT0502. NT0502 is a new chemical entity that is being developed by Neos for the treatment of sialorrhea, which is excessive salivation or drooling. The Company may be required to make certain development and milestone payments and royalties based on annual net sales, as defined in the NeuRx License. Royalties are to be paid on a country-by-country and licensed product-by-licensed product basis, during the period of time beginning on the first commercial sale of such licensed product in such country and continuing until the later of: (i) the expiration of the last-to-expire valid claim in any licensed patent in such country that covers such licensed product in such country; and/or (ii) expiration of regulatory exclusivity of such licensed product in such country. Teva On December 21, 2018, Neos and Teva Pharmaceuticals USA, Inc. (“Teva”) entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla XR-ODT under an Abbreviated New Drug Application (“ANDA”) filed by Teva beginning on July 1, 2026, or earlier under certain circumstances. Actavis On October 17, 2017, Neos entered into an agreement granting Actavis a non-exclusive license to certain patents owned by Neos by which Actavis has the right to manufacture and market its generic version of Adzenys XR-ODT under its ANDA beginning on September 1, 2025, or earlier under certain circumstances. Shire In July 2014, Neos entered into a Settlement Agreement and an associated License Agreement (the “2014 License Agreement”) with Shire LLC (“Shire”) for a non-exclusive license to certain patents for certain activities with respect to Neos’ New Drug Application (the “NDA”) No. 204326 for an extended-release orally disintegrating amphetamine polistirex tablet. In accordance with the terms of the 2014 License Agreement, following the receipt of the approval from the FDA for Adzenys XR-ODT, Neos paid a lump sum, non-refundable license fee of an amount less than $1.0 million in February 2016. Neos is paying a single digit royalty on net sales of Adzenys XR-ODT during the life of the patents. In March 2017, Neos entered into a License Agreement (the “2017 License Agreement”) with Shire, pursuant to which Shire granted Neos a non-exclusive license to certain patents owned by Shire for certain activities with respect to Neos’ NDA No. 204325 for an extended-release amphetamine oral suspension. In accordance with the terms of the 2017 License Agreement, following the receipt of the approval from the FDA for Adzenys ER, Neos paid an up-front, non-refundable license fee of an amount less than $1.0 million in October 2017. Neos is paying a single digit royalty on net sales of Adzenys ER during the life of the patents. Adzenys ER was discontinued as of September 30, 2021. The royalties are recorded as cost of goods sold in the same period as the net sales upon which they are calculated. Additionally, each of the 2014 and 2017 License Agreements contains a covenant from Shire not to file a patent infringement suit against Neos alleging that Adzenys XR-ODT or Adzenys ER, respectively, infringes the Shire patents.

Segment Information

Segment Information	12 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Segment Information	21. Segment Information The Company’s chief operating decision maker, who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance. The Company manages and aggregates its operational and financial information in accordance with two reportable segments: BioPharma and Consumer Health. The BioPharma segment consists of the Company’s prescription products. The Consumer Health segment contains the Company’s consumer healthcare products. During the year ended June 30, 2022, the BioPharma Segment recognized a total impairment loss of $64.6 million related to impairment of goodwill and write-down of assets due to the discontinuance of five non-core products, our Consumer Health segment recognized $10.8 million of goodwill and intangible assets write downs (see Note 8 Goodwill and Other intangible Assets). Select financial information for these segments is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ ​ 2022 2021 ​ ​ (In thousands) Consolidated revenue: ​ ​ ​ BioPharma ​ $ 61,121 ​ $ 32,678 Consumer Health ​ 35,548 ​ 32,954 Consolidated revenue ​ $ 96,669 ​ $ 65,632 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ ​ 2022 2021 ​ ​ (In thousands) Consolidated net loss: ​ ​ BioPharma ​ $ (92,708) ​ $ (50,529) Consumer Health ​ (17,465) ​ (7,760) Consolidated net loss ​ $ (110,173) ​ $ (58,289) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) Total assets: ​ ​ ​ ​ ​ ​ BioPharma ​ $ 121,377 ​ $ 236,449 Consumer Health ​ 16,246 ​ 29,219 Consolidated assets ​ $ 137,623 ​ $ 265,668 ​ ​ ​

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	22. Subsequent Events In August 2022, the Company completed an underwritten public offering of (i) 21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 1,750,000 shares of its common stock, and (ii) accompanying warrants (the "Common Warrants") to purchase 23,255,814 shares of its common stock (the "Offering") resulting in gross and net proceeds of $10.0 million and $9.1 million, respectively, assuming none of the accompanying Common Warrants issued in the Offering are exercised. The pre-funded warrants were exercised in full in August 2022. The Company intends to use the net proceeds from the Offering for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of VEDS, for growth of the company’s commercial business, and for working capital and general corporate purposes. ​ ​

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Principals of Consolidation	Principals of Consolidation .
Basis of Presentation	Basis of Presentation .
Use of Estimates	Use of estimates .
Prior Period Reclassification	Prior Period Reclassification .
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash .
Accounts Receivable	Accounts Receivable .
Inventories	Inventories . The Company periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If evidence exists that the net realizable value of inventory is lower than its cost, the difference is recognized as a loss in the period the impairment is identified.
Going Concern Determination	Going Concern Determination .
Property and equipment	Property and equipment . Furniture equipment two
Leases	Fixed lease payments, or in substance fixed, are recognized over the expected term of the lease using the effective interest method. Variable lease payments are expensed as incurred. Fixed and variable lease expenses on operating leases are recognized within cost of goods sold and operating expenses in the Company’s consolidated statements of operations. ROU asset amortization and interest costs on financing leases are recorded within cost of goods sold and interest expense, respectively, in the Company’s consolidated statements of operations. The Company has elected to account for payments on short-term leases as lease expense on a straight-line basis over lease terms of 12 months or less. Operating leases are included in other liabilities in the Company’s consolidated balance sheets. Financing leases are included in property and equipment, net, current portion of long-term debt and long-term debt, net of current portion in the Company’s consolidated balance sheets.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
Acquisitions and Business Combination and Contingent considerations	Acquisitions . Business Combination and Contingent considerations . The consideration for our acquisitions and certain licensing agreements often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Management estimates the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. The Company revalues its contingent consideration obligations each reporting period using Monte Carlo simulation. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income.
Revenue Recognition	Revenue Recognition . BioPharma segment Net product sales for the BioPharma segment consist of sales of prescription pharmaceutical products under the Rx Portfolio, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx product revenue is recognized at the point in time that control of the product transfers to the customer in accordance with shipping terms (i.e., upon delivery), which is generally “free-on-board” destination when shipped domestically within the United States and “free-on-board” shipping point when shipped internationally consistent with the contractual terms. Rx product revenue is recognized net of consideration paid to the Company’s customers and other adjustments to the transaction price (known as “Gross to Net” adjustments). Estimating adjustments to the transaction price and applying the constraint on variable consideration requires the use of significant management judgment and other market data. Gross to Net adjustments include provisions for product returns, wholesaler distribution fees and chargebacks for discounted pricing to participating entities, managed care rebate programs, savings programs for patients covered under commercial payor plans and other deductions. Consumer Health segment The Consumer Health segment generates its revenue from sales of various consumer health products through direct-to-consumer marketing channels utilizing the Company's proprietary Beyond Human marketing and sales platform and on e-commerce platforms. Revenue is generally recognized “free-on-board” shipping point, as those are the agreed-upon contractual terms. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from a customer are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of sales.
Customer Contract Costs	Customer Contract Costs .
Concentration of Credit Risk	Concentration of Credit Risk . The Company maintains deposits in financial institutions in excess of federally insured limits. The Company periodically monitors the credit quality of the financial institutions with which it invests and believes that the Company is not exposed to significant credit risk due to the financial position of those institutions. The Company is also subject to credit risk from accounts receivable related to product sales. The Company’s customers, sometimes referred to as partners or customers, are primarily large wholesale distributors that resell the Company’s products to retailers. The loss of one or more of these large customers could have a material adverse effect on the Company’s business, operating results or financial condition. The Company does not charge interest or require collateral related to its accounts receivable. Credit terms are generally forty The following table presents customers that contributed more than 10% of gross revenue and accounts receivable : ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Percentage of gross revenue ​ Percentage of accounts receivable ​ ​ June 30, ​ ​ 2022 ​ 2021 ​ 2022 ​ 2021 Customer A ​ 41 % ​ 25 % ​ 52 % ​ 35 % Customer B ​ 20 % ​ 15 % ​ 25 % ​ 29 % Customer C ​ 18 % ​ 14 % ​ 18 % ​ 22 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Costs of Sales	Costs of Sales .
Stock-Based Compensation	Stock-Based Compensation . Restricted stock and restricted stock unit grants are valued based on the estimated grant date fair value of the Company’s common stock and recognized ratably over the requisite service period. Stock option grants are valued using the Black-Scholes option pricing model and compensation costs are recognized ratably over the period of service using the graded method. The Black-Scholes option pricing model requires the Company to estimate the expected term of the award, the expected volatility, the risk-free interest rate, and the expected dividends. The expected term is determined using the “simplified method,” which is the midpoint between the vesting date and the end of the contractual term. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for the expected term of the award. The Company doesn’t anticipate paying any dividends in the near future. Forfeitures are recognized as they occur.
Research and Development	Research and Development
Intangible Assets	Intangible Assets .
Impairment of Long-lived Assets and Goodwill	​ Goodwill is reviewed for impairment at least annually or whenever events or changes in circumstances, including a decline in the Company’s stock price, indicate that its carrying amount is less than its fair value. If qualitative factors, such as general economic conditions, the Company’s outlook and market performance of the Company’s industry forecasted financial performance indicate that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, the Company performs a quantitative analysis of fair value. The Company determines the fair value of a reporting unit utilizing a discounted cash flow model. Significant assumptions inherent in the valuation methodologies include, but are not limited to, prospective financial information, growth rates, terminal value, discount rates and comparable multiples from publicly traded companies in the Company’s industry.
Contingent consideration	Contingent consideration .
Advertising Costs	Advertising Costs .
Income Taxes	Income Taxes . The Company recognizes the effect of income tax positions only if those positions are more likely than not of to be sustained upon an examination. The Company recognizes interest and penalties related to uncertain tax positions in Income tax (provision) benefit in the consolidated statements of operations.
Debt issuance costs, discounts (premium)	Debt issuance costs, discounts (premiums) .
Segment information	Segment information .
Paragraph IV litigation costs	Paragraph IV litigation costs .
Net Loss Per Common Share	Net Loss Per Common Share . the years ended June 30, 2022 and 2021, the Company incurred a net loss and did not include common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive. The following table sets-forth securities excluded from the calculation of diluted earnings per share ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2022 2021 Warrant to purchase common stock (Note 17) ​ 8,688,576 1,279,057 Employee stock options (Note 16) ​ 80,377 109,588 Employee unvested restricted stock (Note 16) ​ 1,607,572 1,955,426 Employee unvested restricted stock units ​ (Note 16) ​ 170,000 ​ 78,318 Total ​ ​ ​ 10,546,525 3,422,389 ​ ​
Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements Simplifying the Accounting for Income Taxes. Simplifying the Accounting for Income Taxes Recent Accounting Pronouncements Not Yet Adopted Debt—Debt with Conversion and Other Options. Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40)— “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” Financial Instruments Credit Losses. ASU 2016-13, “Financial Instruments – Credit Losses” Financial Instruments – Credit Losses Financial Instruments – Credit Losses (topic 326) Troubled Debt Restructurings and Vintage Disclosures Reference Rate Reform. Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting Reference Rate Reform (Topic 848) Earnings Per Share. Earnings Per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on our consolidated financial statements and related disclosures. ​

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Schedule of concentration of business risk	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Percentage of gross revenue ​ Percentage of accounts receivable ​ ​ June 30, ​ ​ 2022 ​ 2021 ​ 2022 ​ 2021 Customer A ​ 41 % ​ 25 % ​ 52 % ​ 35 % Customer B ​ 20 % ​ 15 % ​ 25 % ​ 29 % Customer C ​ 18 % ​ 14 % ​ 18 % ​ 22 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Antidilutive securities excluded from the computation of earnings per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2022 2021 Warrant to purchase common stock (Note 17) ​ 8,688,576 1,279,057 Employee stock options (Note 16) ​ 80,377 109,588 Employee unvested restricted stock (Note 16) ​ 1,607,572 1,955,426 Employee unvested restricted stock units ​ (Note 16) ​ 170,000 ​ 78,318 Total ​ ​ ​ 10,546,525 3,422,389 ​

Revenues from Contracts with _2

Revenues from Contracts with Customers (Tables)	12 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of revenue	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ 2022 2021 ​ ​ (In thousands) ADHD portfolio $ 42,855 $ 10,883 Pediatric portfolio ​ ​ 16,084 ​ ​ 12,437 Consumer Health portfolio ​ ​ 35,548 ​ ​ 32,954 Other ​ ​ 2,182 ​ ​ 9,358 Consolidated revenue $ 96,669 $ 65,632 ​
Schedule of product revenues by geographic location	​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ 2022 2021 ​ ​ (In thousands) U.S. ​ $ 94,606 ​ $ 60,687 International ​ 2,063 ​ 4,945 Total net revenue ​ $ 96,669 ​ $ 65,632 ​

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of assets acquired and liabilities assumed	​ ​ ​ ​ ​ ​ March 19, 2021 ​ ​ (In thousands, except share and per-share) Considerations: ​ ​ ​ Fair Value of Aytu Common Stock ​ ​ ​ Total shares issued at close ​ 5,471,804 Fair value per share of Aytu common stock $ 9.73 Fair value of equity consideration transferred $ 53,241 Cash ​ ​ 15,383 Estimated fair value of replacement equity awards ​ ​ 432 Total consideration transferred $ 69,056 ​ ​ ​ ​ ​ ​ ​ March 19, 2021 ​ ​ (In thousands) Total consideration transferred $ 69,056 Recognized amounts of identified assets acquired and liabilities assumed ​ ​ ​ Cash and cash equivalents $ 15,722 Accounts receivable ​ ​ 24,696 Inventory ​ ​ 10,984 Prepaid expenses and other current assets ​ ​ 2,929 Operating leases right-to-use assets ​ ​ 3,515 Property, plant and equipment ​ ​ 5,519 Intangible assets ​ ​ 56,530 Other long-term assets ​ ​ 149 Accounts payable and accrued expenses ​ ​ (56,718) Short-term line of credit ​ ​ (10,707) Long-term debt, including current portion ​ ​ (17,678) Operating lease liabilities ​ ​ (3,515) Other long-term liabilities ​ ​ (82) Total identifiable net assets ​ 31,344 Goodwill $ 37,712 ​
Schedule of intangible assets acquired	​ ​ ​ ​ ​ ​ ​ March 19, 2021 ​ ​ (In thousands) Identified intangible assets acquired: ​ ​ ​ Developed technology right $ 30,200 Developed products technology ​ ​ 22,700 In-process R&D ​ ​ 2,600 RxConnect ​ ​ 630 Trade name ​ ​ 400 Total intangible assets acquired $ 56,530 ​
Schedule of Pro forma information	​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ 2022 2021 ​ ​ ​ ​ Pro forma ​ ​ Unaudited Unaudited ​ ​ (In thousands) Total revenues, net ​ $ 96,669 ​ $ 98,085 Net loss ​ $ (110,173) ​ $ (74,710) ​

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory balances	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2022 ​ 2021 ​ (In thousands) Raw materials $ 1,814 $ 2,269 Work in process ​ ​ 1,838 ​ ​ 3,346 Finished goods ​ 7,197 ​ 10,724 Inventory, net ​ $ 10,849 ​ $ 16,339 ​

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) Manufacturing equipment ​ $ 2,487 $ 3,070 Leasehold improvements 999 ​ 959 Office equipment, furniture and other 1,128 ​ 1,093 Lab equipment 832 ​ 832 Assets under construction — ​ 198 Property and equipment, gross ​ ​ 5,446 ​ ​ 6,152 Less accumulated depreciation and amortization ​ ​ (2,421) ​ ​ (1,012) Property and equipment, net $ 3,025 ​ $ 5,140 ​

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Schedule of components of lease expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ ​ ​ June 30, ​ ​ ​ 2022 2021 Statement of Operations Classification ​ ​ (In thousands) ​ ​ Lease cost: ​ ​ ​ ​ ​ ​ ​ ​ Operating lease cost ​ $ 1,299 ​ $ 476 Operating expenses Short-term lease cost ​ 152 ​ 109 Operating expenses Finance lease cost: ​ ​ ​ ​ ​ ​ ​ Amortization of leased assets ​ 73 ​ 21 Cost of sales Interest on lease liabilities ​ ​ 14 ​ ​ 6 ​ Other (expense), net Total net lease cost ​ $ 1,538 ​ $ 612 ​
Schedule of balance sheet information related to leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, Balance Sheet Classification ​ ​ 2022 ​ 2021 ​ ​ ​ ​ (In thousands) ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ Operating lease assets ​ $ 3,271 ​ $ 3,563 Operating lease right-of-use asset Finance lease assets ​ ​ 256 ​ 329 Property and equipment, net Total leased assets ​ $ 3,527 ​ $ 3,892 ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ Current: ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ $ 1,227 ​ $ 940 ​ Other current liabilities Finance leases ​ ​ 96 ​ ​ 102 ​ Current portion of debt Non-current ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 2,090 ​ ​ 2,624 ​ Other liabilities Finance leases ​ ​ 84 ​ ​ 180 ​ Debt, net of current portion Total lease liabilities ​ $ 3,497 ​ $ 3,846 ​ ​ ​
Schedule of remaining lease term and discount rate	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2022 ​ 2021 ​ Weighted-Average Remaining Lease Term (years) ​ ​ ​ ​ ​ ​ ​ Operating lease assets ​ 2.63 ​ ​ 3.42 ​ Finance lease assets ​ 1.73 ​ ​ 2.72 ​ Weighted-Average Discount Rate ​ ​ ​ ​ ​ ​ Operating lease assets ​ 7.48 % ​ 6.62 % Finance lease assets ​ ​ 6.43 % ​ 6.41 % ​
Schedule of supplemental cash flow information related to leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ 2022 2021 ​ ​ (In thousands) Cash flow classification of lease payments: ​ ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ $ 1,016 ​ $ 467 Operating cash flows from finance leases ​ $ 15 ​ $ 5 Financing cash flows from finance leases ​ $ 102 ​ $ 25 ​
Schedule of maturities of future minimum lease payments, operating leases	​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Finance ​ ​ (In thousands) 2023 ​ $ 1,436 ​ $ 105 2024 ​ ​ 1,378 ​ ​ 87 2025 ​ ​ 749 ​ ​ — 2026 ​ ​ 90 ​ ​ — 2027 ​ ​ 46 ​ ​ — Total lease payments ​ ​ 3,699 ​ ​ 192 Less: Imputed interest ​ ​ (382) ​ ​ (12) Lease liabilities ​ $ 3,317 ​ $ 180 ​
Schedule of maturities of future minimum lease payments, finance leases	​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Finance ​ ​ (In thousands) 2023 ​ $ 1,436 ​ $ 105 2024 ​ ​ 1,378 ​ ​ 87 2025 ​ ​ 749 ​ ​ — 2026 ​ ​ 90 ​ ​ — 2027 ​ ​ 46 ​ ​ — Total lease payments ​ ​ 3,699 ​ ​ 192 Less: Imputed interest ​ ​ (382) ​ ​ (12) Lease liabilities ​ $ 3,317 ​ $ 180 ​ ​

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of change in carrying amount of goodwill	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ BioPharma Consumer Health Consolidated ​ ​ (In thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance as of June 30, 2020 ​ $ 19,453 ​ $ 8,637 ​ $ 28,090 Goodwill acquired ​ ​ 37,712 ​ ​ — ​ ​ 37,712 Balance as of June 30, 2021 ​ ​ 57,165 ​ ​ 8,637 ​ ​ 65,802 Goodwill impairment ​ (57,165) ​ (8,637) ​ (65,802) Balance as of June 30, 2022 ​ $ — ​ $ — ​ $ — ​
Schedule of finite lived intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology right ​ ​ 45,400 ​ ​ (7,667) ​ ​ (3,224) ​ ​ 34,509 12.33 Acquired technology right ​ ​ 30,200 ​ ​ (2,278) ​ ​ — ​ ​ 27,922 ​ 15.75 Acquired product distribution rights ​ 11,354 ​ (3,581) ​ (2,172) ​ 5,601 7.60 Other intangible assets ​ ​ 4,666 ​ ​ (3,004) ​ ​ (1,662) ​ ​ — ​ — ​ ​ ​ 91,620 ​ ​ (16,530) ​ ​ (7,058) ​ ​ 68,032 ​ 13.35 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ ​ 2,600 ​ ​ — ​ ​ — ​ ​ 2,600 ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ — ​ ​ 2,600 ​ ​ Total ​ $ 94,220 ​ $ (16,530) ​ $ (7,058) ​ $ 70,632 13.35 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Average ​ ​ Carrying ​ Accumulated ​ Net Carrying ​ Remaining ​ Amount Amortization Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology right ​ ​ 45,400 ​ ​ (4,160) ​ ​ 41,240 ​ 12.88 Acquired technology right ​ ​ 30,200 ​ ​ (501) ​ ​ 29,699 ​ 16.75 Acquired product distribution rights ​ ​ 11,354 ​ ​ (2,073) ​ ​ 9,281 ​ 8.57 Other intangible assets ​ ​ 4,666 ​ ​ (2,022) ​ ​ 2,644 ​ 3.05 ​ ​ ​ 91,620 ​ ​ (8,756) ​ ​ 82,864 ​ 13.47 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ 2,600 ​ — ​ 2,600 ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ 2,600 ​ ​ Total ​ $ 94,220 ​ $ (8,756) ​ $ 85,464 ​ 13.47 ​
Schedule of Indefinite lived intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology right ​ ​ 45,400 ​ ​ (7,667) ​ ​ (3,224) ​ ​ 34,509 12.33 Acquired technology right ​ ​ 30,200 ​ ​ (2,278) ​ ​ — ​ ​ 27,922 ​ 15.75 Acquired product distribution rights ​ 11,354 ​ (3,581) ​ (2,172) ​ 5,601 7.60 Other intangible assets ​ ​ 4,666 ​ ​ (3,004) ​ ​ (1,662) ​ ​ — ​ — ​ ​ ​ 91,620 ​ ​ (16,530) ​ ​ (7,058) ​ ​ 68,032 ​ 13.35 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ ​ 2,600 ​ ​ — ​ ​ — ​ ​ 2,600 ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ — ​ ​ 2,600 ​ ​ Total ​ $ 94,220 ​ $ (16,530) ​ $ (7,058) ​ $ 70,632 13.35 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Average ​ ​ Carrying ​ Accumulated ​ Net Carrying ​ Remaining ​ Amount Amortization Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology right ​ ​ 45,400 ​ ​ (4,160) ​ ​ 41,240 ​ 12.88 Acquired technology right ​ ​ 30,200 ​ ​ (501) ​ ​ 29,699 ​ 16.75 Acquired product distribution rights ​ ​ 11,354 ​ ​ (2,073) ​ ​ 9,281 ​ 8.57 Other intangible assets ​ ​ 4,666 ​ ​ (2,022) ​ ​ 2,644 ​ 3.05 ​ ​ ​ 91,620 ​ ​ (8,756) ​ ​ 82,864 ​ 13.47 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ 2,600 ​ — ​ 2,600 ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ 2,600 ​ ​ Total ​ $ 94,220 ​ $ (8,756) ​ $ 85,464 ​ 13.47 ​ ​
Schedule of future amortization expense	​ ​ ​ ​ ​ ​ June 30, ​ ​ (In thousands) 2023 ​ $ 6,086 2024 ​ ​ 6,074 2025 ​ ​ 5,934 2026 ​ ​ 5,683 2027 ​ ​ 5,653 Thereafter ​ ​ 38,602 Total future amortization expense ​ $ 68,032 ​

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Jun. 30, 2022
Accrued Liabilities, Current [Abstract]
Schedule of Accrued liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) ​ ​ ​ ​ ​ ​ ​ Accrued savings offers ​ $ 12,711 ​ $ 20,148 Accrued program liabilities ​ ​ 9,468 ​ ​ 8,689 Return reserve ​ 5,770 ​ 6,367 Accrued compensation ​ ​ 4,765 ​ ​ 5,939 Accrued customer and product related fees ​ ​ 7,817 ​ ​ 12,346 Other accrued liabilities ​ ​ 3,656 ​ ​ 3,745 Total accrued liabilities ​ $ 44,187 ​ $ 57,234 ​

Other Liabilities (Tables)

Other Liabilities (Tables)	12 Months Ended
	Jun. 30, 2022
Other Liabilities Disclosure [Abstract]
Schedule of other liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) ​ ​ ​ ​ ​ ​ ​ Contingent consideration ​ $ 396 ​ $ 12,057 Fixed payment arrangement ​ ​ 13,051 ​ ​ 9,458 Operating lease liabilities ​ 3,317 ​ 3,564 Contingent value rights ​ ​ 578 ​ ​ 1,395 Other ​ ​ 827 ​ ​ 355 Total other liabilities ​ ​ 18,169 ​ ​ 26,829 Less: current portion ​ ​ (5,359) ​ ​ (8,347) Total other liabilities, noncurrent ​ $ 12,810 ​ $ 18,482 ​

Long-term Debt (Tables)

Long-term Debt (Tables)	12 Months Ended
	Jun. 30, 2022
Long-term Debt
Schedule of long term debt	​ ​ ​ ​ ​ ​ June 30, ​ ​ 2022 ​ ​ (In thousands) Long-term debt, due on January 26, 2025 ​ $ 15,000 Long-term, final payment fee ​ ​ 638 Unamortized discount and issuance costs ​ ​ (1,443) Financing leases, maturing through May 2024 ​ ​ 180 Total debt ​ ​ 14,375 Less: current portion ​ ​ (96) Non-current portion of debt ​ $ 14,279
Schedule of future principal payments of long term debt	​ ​ ​ ​ ​ ​ June 30, ​ ​ (In thousands) 2023 ​ $ 96 2024 ​ ​ 8,418 2025 ​ ​ 7,304 Future principal payments ​ ​ 15,818 Less unamortized discount and issuance costs ​ ​ (1,443) Less current portion ​ ​ (96) Non-current portion of debt ​ $ 14,279

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Jun. 30, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Schedule of fair value on a recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at June 30, 2022 ​ Fair Value at June 30, ​ ​ ​ ​ ​ 2022 (Level 1) (Level 2) (Level 3) ​ ​ (In thousands) Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 19,360 ​ $ 19,360 ​ $ — ​ $ — Total ​ $ 19,360 $ 19,360 $ — ​ $ — Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration $ 396 $ — $ — $ 396 CVR liability ​ 578 ​ — ​ — ​ 578 Warrant ​ ​ — ​ — ​ — ​ — Total ​ $ 974 $ — $ — ​ $ 974 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at June 30, 2021 ​ Fair Value at June 30, ​ ​ ​ ​ ​ 2021 (Level 1) (Level 2) (Level 3) ​ (In thousands) Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 49,649 ​ $ 49,649 ​ $ — ​ $ — Total ​ $ 49,649 $ 49,649 $ — ​ $ — Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration ​ $ 12,057 $ — $ — $ 12,057 CVR liability ​ ​ 1,395 ​ — ​ — ​ 1,395 Total ​ $ 13,452 $ — $ — ​ $ 13,452 ​
Schedule of fair value on a nonrecurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at June 30, 2022 ​ Fair Value at June 30, ​ ​ ​ ​ ​ 2022 (Level 1) (Level 2) (Level 3) ​ ​ (In thousands) Non-recurring ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fixed payment arrangements ​ $ 13,051 ​ $ — ​ $ — ​ $ 13,051 Total ​ $ 13,051 $ — $ — ​ $ 13,051 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at June 30, 2021 ​ Fair Value at June 30, ​ ​ ​ ​ ​ 2021 (Level 1) (Level 2) (Level 3) ​ ​ (In thousands) Non-recurring ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fixed payment arrangements ​ $ 9,458 ​ $ — ​ $ — ​ $ 9,458 Total ​ $ 9,458 $ — $ — ​ $ 9,458 ​
Schedule of changes in Level 3 inputs	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CVR Contingent Fixed Payment ​ ​ Warrant ​ ​ Liability ​ Consideration ​ Arrangements ​ ​ Liability ​ ​ (In thousands) Balance as of June 30, 2021 $ 1,395 ​ $ 12,057 $ 9,458 ​ $ — Included in earnings ​ (817) ​ ​ 604 ​ 1,148 ​ ​ (211) Purchases, issues, sales and settlements: ​ ​ ​ ​ ​ ​ ​ Issues — ​ — 7,645 ​ 590 Settlements * — ​ (12,265) (5,200) ​ (379) Balance as of June 30, 2022 $ 578 ​ $ 396 $ 13,051 ​ $ — * Including $9.1 million reversal of contingent consideration liabilities see Note 10 Other Liabilities and $0.4 million liability warrants reclassified to equity
Contingent Value Rights
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Schedule of significant assumptions used in valuation	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ 2022 ​ 2021 Leveraged Beta 0.85 ​ 0.91 ​ Market risk premium ​ 6.22 % ​ 6.00 % Risk-free interest rate ​ 2.86 % ​ 0.36 % Discount ​ 20.50 % ​ 13.00 % Company specific discount 10.00 % 5.00 % ​
Derivative Financial Instruments, Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Schedule of significant assumptions used in valuation	​ ​ ​ ​ ​ ​ ​ January 26, ​ 2022 Expected volatility 56.75 % Equivalent term (years) ​ 5.00 ​ Risk-free rate ​ 1.66 % Dividend yield ​ 0.00 % ​
Fixed Payment Arrangements
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Schedule of significant assumptions used in valuation	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ 2022 2021 Discount rate - minimum 10.0 % 10.0 % Discount rate - maximum ​ 15.4 % ​ 12.4 % ​

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Provision for income taxes	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) Current: ​ ​ ​ ​ ​ ​ Federal ​ $ — ​ $ — State ​ 7 ​ 16 Total current tax expense ​ 7 ​ 16 Deferred: ​ ​ ​ ​ Federal ​ (91) ​ 200 State ​ (26) ​ 43 Total deferred tax expense ​ (117) ​ 243 Provision for income taxes ​ $ (110) ​ $ 259 ​
Effective income tax rate reconciliation	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2022 ​ ​ 2021 ​ ​ (In thousands) Tax at statutory rate ​ $ (23,159) ​ (21.00) % ​ $ (12,185) ​ (21.00) % State income taxes, net of federal benefit ​ ​ 601 ​ 0.55 % ​ ​ (2,461) ​ (4.24) % Permanent difference ​ ​ — ​ — % ​ ​ — ​ — % Stock based compensation ​ ​ 273 ​ 0.27 % ​ ​ 43 ​ 0.07 % Contingent consideration ​ ​ (155) ​ (0.14) % ​ ​ (667) ​ (1.15) % 162(m) limitation ​ ​ 76 ​ 0.08 % ​ ​ 235 ​ 0.40 % Goodwill impairment ​ ​ 9,733 ​ 8.83 % ​ ​ — ​ — % Transaction costs ​ ​ — ​ — % ​ ​ 160 ​ 0.28 % Change in tax rate ​ ​ — ​ — % ​ ​ — ​ — % Remeasurement of deferred taxes ​ ​ — ​ — % ​ ​ — ​ — % Effect of phased-in tax rate ​ ​ — ​ — % ​ ​ — ​ — % Loss on debt extinguishment and interest expense ​ ​ — ​ — % ​ ​ — ​ — % Change in valuation allowance ​ ​ 12,472 ​ 11.31 % ​ ​ 14,483 ​ 24.96 % Derivative income ​ ​ — ​ — % ​ ​ — ​ — % Other ​ ​ 49 ​ 0.01 % ​ ​ 651 ​ 1.13 % Net income tax provision (benefit) ​ $ (110) ​ (0.09) % ​ $ 259 ​ 0.45 % ​
Deferred tax assets and liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) Deferred tax assets: ​ ​ ​ ​ ​ ​ Net operating loss carry forward ​ $ 114,443 ​ $ 106,712 Accrued Rebates ​ ​ 5,944 ​ ​ 8,412 Share-based compensation ​ 2,773 ​ 2,330 Accrued expenses ​ ​ 817 ​ ​ 1,507 R&D credits ​ 2,423 ​ 2,115 Interest ​ ​ 2,975 ​ ​ 2,064 Inventory ​ 1,177 ​ 1,704 Lease liability ​ 799 ​ 1,031 Other ​ ​ 1,301 ​ ​ 1,526 Total deferred tax assets ​ ​ 132,652 ​ ​ 127,401 Less: valuation allowance ​ ​ (128,966) ​ ​ (116,494) Deferred tax assets, net of valuation allowance ​ ​ 3,686 ​ ​ 10,907 Deferred tax liabilities: ​ ​ ​ ​ ​ ​ Intangibles ​ (2,717) ​ (9,396) ROU asset ​ (308) ​ (1,009) Fixed assets ​ ​ (788) ​ ​ (745) Total deferred tax liabilities ​ ​ (3,813) ​ ​ (11,150) Net deferred tax liabilities ​ $ (127) ​ $ (243) ​
Tabular rollforward of gross unrecognized tax benefits	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) Beginning balance ​ $ 11,537 ​ $ — Increase resulting from prior period tax positions ​ — ​ 12,017 Increase resulting from current period tax positions ​ ​ — ​ ​ 2 Decrease resulting from current period tax positions ​ (1,704) ​ (482) Ending balance ​ $ 9,833 ​ $ 11,537 ​

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	12 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average ​ Contractual ​ ​ Options ​ Exercise Price ​ Life in Years Outstanding June 30, 2021 109,588 ​ $ 14.52 8.07 Forfeited/Cancelled (15,569) ​ ​ 7.98 Expired (13,642) ​ ​ 9.65 Outstanding at June 30, 2022 80,377 ​ $ 16.61 7.77 ​ ​ ​ ​ ​ ​ ​ ​ Exercisable at June 30, 2022 54,649 ​ $ 20.58 7.77
Stock options outstanding	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Remaining ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ Contractual ​ ​ ​ ​ ​ Range of ​ Number of ​ Average ​ Life of ​ Number of ​ Weighted Exercise ​ Options ​ Exercise ​ Options ​ Options ​ Average Prices ​ Outstanding ​ Price ​ Outstanding ​ Exercisable ​ Exercise Price $ 6.2 - 9.70 38,998 ​ $ 6.44 7.65 19,882 ​ $ 6.50 $ 9.80 - 14.70 41,225 ​ $ 14.13 7.90 34,613 ​ $ 14.28 $ 2,800.00 - 4,200.00 154 ​ $ 3,255.06 3.80 154 ​ $ 3,255.06 ​ ​ 80,377 ​ $ 16.61 7.77 54,649 ​ $ 20.58
Restricted stock activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2021 1,955,268 ​ $ 7.83 Granted 295,000 ​ ​ 3.67 Vested (642,696) ​ ​ 6.81 Unvested at June 30, 2022 1,607,572 ​ $ 7.47
Restricted stock units activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2021 78,318 ​ $ 7.20 Granted ​ 170,000 ​ ​ 1.29 Vested (15,396) ​ ​ 6.20 Forfeited ​ (62,922) ​ ​ 7.44 Unvested at June 30, 2022 170,000 ​ $ 1.29
Stock-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ ​ 2022 2021 ​ ​ (In thousands) Cost of sales ​ $ 31 ​ $ 16 Research and development ​ ​ 536 ​ ​ 68 Selling and marketing ​ ​ 24 ​ ​ 27 General and Administrative ​ 4,657 ​ 3,463 Total stock-based compensation expense ​ $ 5,248 ​ $ 3,574

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Jun. 30, 2022
Class of Warrant or Right [Line Items]
Schedule of equity-based warrants	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average ​ Contractual ​ ​ Warrants ​ Exercise Price ​ Life in Years Outstanding June 30, 2021 1,254,952 ​ $ 35.85 2.83 Warrants issued 10,563,769 ​ 0.92 5.12 Warrants exercised ​ (3,030,000) ​ ​ 0.00 ​ — Warrants expired (124,250) ​ 124.69 — Outstanding June 30, 2022 8,664,471 ​ $ 4.63 4.73 ​
Warrants to Purchase Common Stock, Equity Classified
Class of Warrant or Right [Line Items]
Schedule of significant assumptions used in valuation	​ ​ ​ ​ ​ ​ ​ March 7, ​ ​ 2022 Valuation method ​ Black-Scholes ​ Expected volatility 54.45 % Equivalent term (years) ​ 4.89 - 5.00 ​ Risk-free rate ​ 1.71 % Dividend yield ​ 0.00 % ​

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Schedule of segment financial information, consolidated revenue	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ ​ 2022 2021 ​ ​ (In thousands) Consolidated revenue: ​ ​ ​ BioPharma ​ $ 61,121 ​ $ 32,678 Consumer Health ​ 35,548 ​ 32,954 Consolidated revenue ​ $ 96,669 ​ $ 65,632 ​
Schedule of segment financial information, consolidated net loss	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ ​ 2022 2021 ​ ​ (In thousands) Consolidated net loss: ​ ​ BioPharma ​ $ (92,708) ​ $ (50,529) Consumer Health ​ (17,465) ​ (7,760) Consolidated net loss ​ $ (110,173) ​ $ (58,289) ​
Schedule of segment financial information, total assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) Total assets: ​ ​ ​ ​ ​ ​ BioPharma ​ $ 121,377 ​ $ 236,449 Consumer Health ​ 16,246 ​ 29,219 Consolidated assets ​ $ 137,623 ​ $ 265,668 ​

Nature of Business and Financ_2

Nature of Business and Financial Condition - Segments (Details) - segment	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of reportable segments	2	2

Nature of Business and Financ_3

Nature of Business and Financial Condition - Product Information (Details) - product	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Number of product candidates in development	2
Consumer Health Portfolio | Minimum
Disaggregation of Revenue [Line Items]
Number of products	20	20

Nature of Business and Financ_4

Nature of Business and Financial Condition - General Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash, cash equivalents and restricted cash	$ 19,360	$ 49,901	$ 48,333
Net Income (Loss) Attributable to Parent [Abstract]
Net loss	(110,173)	(58,289)
Retained Earnings (Accumulated Deficit) [Abstract]
Accumulated deficit	(288,472)	(178,299)
Net Cash Provided by (Used in) Operating Activities [Abstract]
Cash used in operations	$ (28,823)	$ (25,964)

Nature of Business and Financ_5

Nature of Business and Financial Condition - Underwritten Public Offering - Common Stock (Details) - Underwritten Public Offering, August 2022 - Subsequent Event $ in Millions	1 Months Ended
	Aug. 31, 2022 USD ($) shares
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares) | shares	21,505,814
Proceeds from issuance of common stock and warrants	$ 10
Proceeds from issuance of common stock and warrants, net of issuance costs	$ 9.1

Nature of Business and Financ_6

Nature of Business and Financial Condition - Underwritten Public Offering - Warrants (Details) - Subsequent Event	Aug. 31, 2022 shares
Warrants to Purchase Common Stock, Equity Classified, Common Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	1,750,000
Warrants to Purchase Common Stock, Equity Classified, Pre-funded Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	23,255,814

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash, cash equivalents and restricted cash	$ 19,360	$ 49,901	$ 48,333

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Accounts Receivable (Details) - USD ($) $ in Millions	Jun. 30, 2021	Jun. 30, 2020
Accounts Receivable, after Allowance for Credit Loss [Abstract]
Allowance for doubtful accounts	$ 1	$ 0
Reserve for cash discount	1.2	1.3
Reserve for chargebacks	$ 1	$ 1.2

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Property and Equipment (Details)	12 Months Ended
	Jun. 30, 2022
Equipment | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	2 years
Equipment | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years
Furniture and Fixtures | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	2 years
Furniture and Fixtures | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	shorter of the estimated useful life or remaining lease term

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Concentration of Credit Risk - General Information (Details)	12 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Accounts receivable, credit terms, low end of range	40 days
Accounts receivable, credit terms, high end of range	60 days

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Concentration of Credit Risk - Tabular Disclosure (Details)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Customer A
Concentration Risk [Line Items]
Concentration risk (as a percent)	41%	25%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Customer B
Concentration Risk [Line Items]
Concentration risk (as a percent)	20%	15%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Customer C
Concentration Risk [Line Items]
Concentration risk (as a percent)	18%	14%
Accounts Receivable | Credit Concentration Risk | Customer A
Concentration Risk [Line Items]
Concentration risk (as a percent)	52%	35%
Accounts Receivable | Credit Concentration Risk | Customer B
Concentration Risk [Line Items]
Concentration risk (as a percent)	25%	29%
Accounts Receivable | Credit Concentration Risk | Customer C
Concentration Risk [Line Items]
Concentration risk (as a percent)	18%	22%

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Advertising Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Marketing and Advertising Expense [Abstract]
Advertising costs	$ 13.6	$ 15.2

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Segment Information (Details) - segment	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of reportable segments	2	2

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) - shares	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	10,546,525	3,422,389
Warrants to Purchase Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	8,688,576	1,279,057
Share-Based Payment Arrangement, Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	80,377	109,588
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,607,572	1,955,426
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	170,000	78,318

Summary of Significant Accou_11

Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)	Jun. 30, 2022
Accounting Standards Update 2019-12
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jul. 01, 2021
Accounting Standards Update 2020-06
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	false
Accounting Standards Update 2016-13
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	false
Accounting Standards Update 2020-04
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	false
Accounting Standards Update 2021-04
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	false

Revenue Recognition - General I

Revenue Recognition - General Information (Details)	12 Months Ended
	Jun. 30, 2022 product item	Jun. 30, 2021 item product
Disaggregation of Revenue [Line Items]
Number of product portfolios | item	3	3
Consumer Health Portfolio | Minimum
Disaggregation of Revenue [Line Items]
Number of products | product	20	20

Revenue Recognition - Discontin

Revenue Recognition - Discontinued or Divested Non-core Products (Details) - Non-core Products, Cefaclor, Flexichamber, Tussionex, Tuzistra XR, and Zolpimist - Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations $ in Millions	12 Months Ended
	Jun. 30, 2022 USD ($)
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Net revenue	$ 2.1
Gross profit (loss)	$ (0.6)

Revenue Recognition - Revenues

Revenue Recognition - Revenues by Product Portfolio (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 96,669	$ 65,632
Attention Deficit Hyperactivity Disorder Portfolio
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	42,855	10,883
Pediatric Portfolio
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	16,084	12,437
Consumer Health Portfolio
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	35,548	32,954
Other Product Portfolio
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 2,182	$ 9,358

Revenue Recognition - Revenue_2

Revenue Recognition - Revenues by Geographic Location (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 96,669	$ 65,632
UNITED STATES
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	94,606	60,687
Non-US
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 2,063	$ 4,945

Acquisitions - General Informat

Acquisitions - General Information (Details) - USD ($) $ in Thousands		12 Months Ended
	Mar. 19, 2021	Jun. 30, 2022	Jun. 30, 2021
Business Combination, Description [Abstract]
Acquisition related costs		$ 0	$ 2,919
Neos Therapeutics, Inc.
Business Acquisition, Date of Acquisition [Abstract]
Business acquisition, effective date of acquisition	Mar. 19, 2021
Business Combination, Description [Abstract]
Business acquisition, equity interest issued or issuable, number of shares (in shares)	5,471,804
Acquisition related costs	$ 2,900
Issuance costs	$ 100

Acquisitions - Considerations (

Acquisitions - Considerations (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Mar. 19, 2021	Jun. 30, 2022	Jun. 30, 2021
Business Combination, Consideration Transferred [Abstract]
Cash		$ 0	$ 15,520
Neos Therapeutics, Inc.
Business Combination, Consideration Transferred [Abstract]
Total shares issued at close (in shares)	5,471,804
Fair value per share of Aytu common stock (in dollars per share)	$ 9.73
Fair value of equity consideration transferred	$ 53,241
Cash	15,383
Estimated fair value of replacement equity awards	432
Total consideration transferred	$ 69,056

Acquisitions - Assets Acquired

Acquisitions - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021	Mar. 19, 2021	Jun. 30, 2020
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Goodwill	$ 0	$ 65,802		$ 28,090
Neos Therapeutics, Inc.
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Total consideration transferred			$ 69,056
Cash and cash equivalents			15,722
Accounts receivable			24,696
Inventory			10,984
Prepaid expenses and other current assets			2,929
Operating leases right-to-use assets			3,515
Property, plant and equipment			5,519
Intangible assets			56,530
Other long-term assets			149
Accounts payable and accrued expenses			(56,718)
Short-term line of credit			(10,707)
Long-term debt, including current portion			(17,678)
Operating lease liabilities			(3,515)
Other long-term liabilities			(82)
Total identifiable net assets			31,344
Goodwill			$ 37,712

Acquisitions - Identifiable Int

Acquisitions - Identifiable Intangible Assets Acquired - Finite-lived Intangible Assets (Details) - Neos Therapeutics, Inc. $ in Thousands	Mar. 19, 2021 USD ($)
Developed Technology Rights
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 30,200
Developed Products Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	22,700
RXConnect
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	630
Trade Names
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 400

Acquisitions - Identifiable I_2

Acquisitions - Identifiable Intangible Assets Acquired - Total Intangible Assets (Details) - Neos Therapeutics, Inc. $ in Thousands	Mar. 19, 2021 USD ($)
Business Acquisition [Line Items]
Indefinite-lived intangible assets acquired, In-process R&D	$ 2,600
Total intangible assets acquired	$ 56,530

Acquisitions - Identifiable I_3

Acquisitions - Identifiable Intangible Assets Acquired - General Information (Details) - Neos Therapeutics, Inc.	Mar. 19, 2021
Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	1 year
Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	17 years

Acquisitions - Unaudited Pro Fo

Acquisitions - Unaudited Pro Forma Results (Details) - Neos Therapeutics, Inc. - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Business Acquisition, Pro Forma Information [Abstract]
Total revenues, net	$ 96,669	$ 98,085
Net loss	$ (110,173)	$ (74,710)

Acquisitions - Asset Acquisitio

Acquisitions - Asset Acquisitions (Details) - AR101 $ in Millions	Apr. 12, 2021 USD ($)
Asset Acquisition [Line Items]
Asset acquisition, date of acquisition agreement	Apr. 12, 2021
Asset Acquisition, Consideration Transferred [Abstract]
Up-front fee	$ 1.5
Aggregated fees	0.6
Contingent consideration	$ 67.5

Inventories - Tabular Disclosur

Inventories - Tabular Disclosure (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Inventory, Net [Abstract]
Raw materials	$ 1,814	$ 2,269
Work in process	1,838	3,346
Finished goods	7,197	10,724
Inventory, net	$ 10,849	$ 16,339

Inventories - Additional Inform

Inventories - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Production Related Impairments or Charges [Abstract]
Inventory write-down and impairment	$ 4.2	$ 7.3

Property and Equipment - Tabula

Property and Equipment - Tabular Disclosure (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	$ 5,446	$ 6,152
Less accumulated depreciation and amortization	(2,421)	(1,012)
Property and equipment, net	3,025	5,140
Manufacturing Equipment
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	2,487	3,070
Leasehold Improvements
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	999	959
Office Equipment, Furniture and Other
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	1,128	1,093
Lab Equipment
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	$ 832	832
Asset under Construction
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Less accumulated depreciation and amortization		$ (198)

Property and Equipment - Deprec

Property and Equipment - Depreciation Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Depreciation, Depletion and Amortization [Abstract]
Depreciation expense	$ 1.6	$ 0.6

Property and Equipment - Gain (

Property and Equipment - Gain (Loss) on Disposal (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Gain (Loss) on Disposition of Property Plant Equipment [Abstract]
Gain (loss) on sale of equipment	$ 0.1	$ (0.1)

Property and Equipment - Impair

Property and Equipment - Impairment (Details) - Manufacturing Equipment $ in Millions	12 Months Ended
	Jun. 30, 2022 USD ($)
Impairment, Long-Lived Asset, Held-for-Use [Abstract]
Impairment charge	$ 0.2
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income	Impairment expense

Leases - General Information (D

Leases - General Information (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021	Mar. 19, 2021
Lessee, Operating Lease, Description [Abstract]
Operating lease right-of-use asset	$ 3,271	$ 3,563
Operating lease liabilities	3,317	$ 3,564
Office Space and Manufacturing Facilities, Grand Prairie, Texas
Lessee, Operating Lease, Description [Abstract]
Operating lease right-of-use asset			$ 3,500
Operating lease liabilities			$ 3,500
Operating lease, borrowing rate (as a percent)			6.70%
Lessee, Finance Lease, Description [Abstract]
Finance leases, interest rate (as a percent)			5.90%
Operating Leases, Fiscal Years 2021 and 2022
Lessee, Operating Lease, Description [Abstract]
Operating lease right-of-use asset	500
Operating lease liabilities	$ 500

Leases - Net Lease Cost (Detail

Leases - Net Lease Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Lease, Cost [Abstract]
Operating lease cost	$ 1,299	$ 476
Short-term lease cost	152	109
Amortization of leased assets	73	21
Interest on lease liabilities	14	6
Total net lease cost	$ 1,538	$ 612

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Assets and Liabilities, Lessee [Abstract]
Operating lease assets	$ 3,271	$ 3,563
Finance lease assets	$ 256	$ 329
Finance Lease, Right-of-Use Asset, Statement of Financial Position	Property and equipment, net	Property and equipment, net
Total leased assets	$ 3,527	$ 3,892
Current portion of operating lease liabilities	$ 1,227	$ 940
Operating Lease, Liability, Current, Statement of Financial Position	Other current liabilities	Other current liabilities
Finance leases, current	$ 96	$ 102
Finance Lease, Liability, Current, Statement of Financial Position	Current portion of debt	Current portion of debt
Operating lease liabilities, net of current portion	$ 2,090	$ 2,624
Operating Lease, Liability, Noncurrent, Statement of Financial Position	Other non-current liabilities	Other non-current liabilities
Finance leases, long-term	$ 84	$ 180
Finance Lease, Liability, Noncurrent, Statement of Financial Position	Debt, net of current portion	Debt, net of current portion
Total lease liabilities	$ 3,497	$ 3,846

Leases - Remaining Lease Term a

Leases - Remaining Lease Term and Weighted-average Discount Rate (Details)	Jun. 30, 2022	Jun. 30, 2021
Lessee Disclosure [Abstract]
Operating lease assets, weighted-average remaining lease term	2 years 7 months 17 days	3 years 5 months 1 day
Finance lease assets, weighted-average remaining lease term	1 year 8 months 23 days	2 years 8 months 19 days
Operating lease assets, weighted-average discount rate	7.48%	6.62%
Finance lease assets, weighted-average discount rate	6.43%	6.41%

Leases - Cash Flow Information

Leases - Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash Flow, Operating Activities, Lessee [Abstract]
Operating cash flows from operating leases	$ 1,016	$ 467
Cash Flow, Investing Activities, Lessee [Abstract]
Operating cash flows from finance leases	15	5
Cash Flow, Financing Activities, Lessee [Abstract]
Financing cash flows from finance leases	$ 102	$ 25

Leases - Operating Leases - Fut

Leases - Operating Leases - Future Minimum Lease Payments (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2023	$ 1,436
2024	1,378
2025	749
2026	90
2027	46
Total lease payments	$ 3,699

Leases - Operating Leases - Gro

Leases - Operating Leases - Gross Difference (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Operating Lease Liabilities, Gross Difference, Amount [Abstract]
Total lease payments	$ 3,699
Less: Imputed interest	(382)
Lease liabilities	$ 3,317	$ 3,564

Leases - Finance Leases - Futur

Leases - Finance Leases - Future Minimum Lease Payments (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Finance Lease, Liability, Payment, Due [Abstract]
2023	$ 105
2024	87
Total lease payments	$ 192

Leases - Finance Leases - Gross

Leases - Finance Leases - Gross Difference (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Finance Lease Liabilities, Gross Difference, Amount [Abstract]
Total lease payments	$ 192
Less: Imputed interest	(12)
Lease liabilities	$ 180

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Change in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 65,802	$ 28,090
Goodwill acquired		37,712
Goodwill impairment	(65,802)
Goodwill, ending balance	0	65,802
BioPharma
Goodwill [Roll Forward]
Goodwill, beginning balance	57,165	19,453
Goodwill acquired		37,712
Goodwill impairment	(57,165)
Goodwill, ending balance		57,165
Consumer Health
Goodwill [Roll Forward]
Goodwill, beginning balance	8,637	8,637
Goodwill impairment	$ (8,637)
Goodwill, ending balance		$ 8,637

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Goodwill Impairment (Details) $ in Thousands	12 Months Ended
	Jun. 30, 2022 USD ($)
Asset Impairment Charges [Abstract]
Goodwill impairment	$ 65,802
BioPharma
Asset Impairment Charges [Abstract]
Goodwill impairment	57,165
Consumer Health
Asset Impairment Charges [Abstract]
Goodwill impairment	$ 8,637

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	$ 91,620	$ 91,620
Accumulated amortization	(16,530)	(8,756)
Impairment	(7,058)
Finite-lived intangible assets, net	68,032	82,864
Product Technology Right
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	45,400	45,400
Accumulated amortization	(7,667)	(4,160)
Impairment	(3,224)
Finite-lived intangible assets, net	34,509	41,240
Developed Technology Rights
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	30,200	30,200
Accumulated amortization	(2,278)	(501)
Finite-lived intangible assets, net	27,922	29,699
Product Distribution Rights
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	11,354	11,354
Accumulated amortization	(3,581)	(2,073)
Impairment	(2,172)
Finite-lived intangible assets, net	5,601	9,281
Other Intangible Assets
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	4,666	4,666
Accumulated amortization	(3,004)	(2,022)
Impairment	(1,662)
Finite-lived intangible assets, net	$ 0	$ 2,644

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets - Weighted-average Remaining Life (Details)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	13 years 4 months 6 days
Weighted Average
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period		13 years 5 months 19 days
Product Technology Right
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	12 years 3 months 29 days
Product Technology Right | Weighted Average
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period		12 years 10 months 17 days
Developed Technology Rights
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	15 years 9 months
Developed Technology Rights | Weighted Average
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period		16 years 9 months
Product Distribution Rights
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	7 years 7 months 6 days
Product Distribution Rights | Weighted Average
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period		8 years 6 months 25 days
Other Intangible Assets | Weighted Average
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period		3 years 18 days

Goodwill and Other Intangible_7

Goodwill and Other Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Finite-lived intangible assets, gross carrying amount	$ 91,620	$ 91,620
Indefinite-lived intangible assets	2,600	2,600
Intangible assets, gross carrying amount	94,220	94,220
Accumulated amortization	(16,530)	(8,756)
Impairment	(7,058)
Intangible assets, net carrying amount	$ 70,632	$ 85,464

Goodwill and Other Intangible_8

Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2023	$ 6,086
2024	6,074
2025	5,934
2026	5,683
2027	5,653
Thereafter	38,602
Finite-lived intangible assets, net	$ 68,032	$ 82,864

Goodwill and Other Intangible_9

Goodwill and Other Intangible Assets - Supply and Distribution Agreement (Details)	12 Months Ended
	Jun. 30, 2022
Supply and Distribution Agreement, Tris Pharma, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Supply and distribution agreement, term	20 years

Goodwill and Other Intangibl_10

Goodwill and Other Intangible Assets - Estimated Useful Life (Details)	12 Months Ended
	Jun. 30, 2022
Minimum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life, renewable period	1 year
Maximum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life, renewable period	20 years
Product Technology Right | Attention Deficit Hyperactivity Disorder Portfolio
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	17 years

Goodwill and Other Intangibl_11

Goodwill and Other Intangible Assets - Product Distribution Rights and Customer List (Details) - Innovus Pharmaceuticals, Inc	1 Months Ended
	Feb. 29, 2020 item product
Business Acquisition [Line Items]
Number of products acquired | product	35
Number of registered trademarks and or patent rights and customer lists acquired | item	300

Goodwill and Other Intangibl_12

Goodwill and Other Intangible Assets - Amortization Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Amortization [Abstract]
Amortization expense	$ 7.8	$ 7.1

Goodwill and Other Intangibl_13

Goodwill and Other Intangible Assets - Intangible Assets Impairment (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Asset Impairment Charges [Abstract]
Impairment of intangible assets, finite-lived	$ 4.9
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income	Impairment expense
Consumer Health
Asset Impairment Charges [Abstract]
Impairment of intangible assets, finite-lived	$ 2.2
BioPharma
Asset Impairment Charges [Abstract]
Impairment of intangible assets, finite-lived		$ 12.8
Trade Names
Asset Impairment Charges [Abstract]
Impairment of intangible assets, finite-lived	0.2
AcipHex
Asset Impairment Charges [Abstract]
Impairment of intangible assets, finite-lived	2.6
ZolpiMist
Asset Impairment Charges [Abstract]
Impairment of intangible assets, finite-lived	1.4
Tussionex
Asset Impairment Charges [Abstract]
Impairment of intangible assets, finite-lived	0.5
Cefaclor
Asset Impairment Charges [Abstract]
Impairment of intangible assets, finite-lived	$ 0.2
Natesto | BioPharma
Asset Impairment Charges [Abstract]
Impairment of intangible assets, finite-lived		4.3
Tuzistra XR | BioPharma
Asset Impairment Charges [Abstract]
Impairment of intangible assets, finite-lived		$ 8.5

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Accrued Liabilities, Current [Abstract]
Accrued savings offers	$ 12,711	$ 20,148
Accrued program liabilities	9,468	8,689
Return reserve	5,770	6,367
Accrued compensation	4,765	5,939
Accrued customer and product related fees	7,817	12,346
Other accrued liabilities	3,656	3,745
Total accrued liabilities	$ 44,187	$ 57,234

Other Liabilities - Components

Other Liabilities - Components (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Other Liabilities, Unclassified [Abstract]
Contingent consideration	$ 396	$ 12,057
Fixed payment arrangements	13,051	9,458
Operating lease liabilities	3,317	3,564
Contingent value rights	578	1,395
Other	827	355
Total other liabilities	$ 18,169	$ 26,829

Other Liabilities - Classificat

Other Liabilities - Classification (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Other Liabilities [Abstract]
Total other liabilities	$ 18,169	$ 26,829
Less: current portion	(5,359)	(8,347)
Total other liabilities, noncurrent	$ 12,810	$ 18,482

Other Liabilities - Fixed Payme

Other Liabilities - Fixed Payment Arrangements (Details) $ in Thousands				1 Months Ended		12 Months Ended
	May 12, 2022 USD ($) payment	Jun. 21, 2021 USD ($)	May 29, 2020 USD ($)	Jan. 31, 2021 USD ($)	Jan. 31, 2020 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Sep. 30, 2021 USD ($) payment	Nov. 01, 2019 USD ($) agreement
Other Commitments [Line Items]
Fixed payment arrangements						$ 13,051	$ 9,458
(Gain) loss on debt extinguishment						(169)	1,569
Issues, fixed payment arrangements						7,645
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc
Other Commitments [Line Items]
Fixed payment arrangements, periodic payment obligations, number | agreement									2
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Fixed Payments
Other Commitments [Line Items]
Fixed payment arrangements, monthly payment amount									$ 100
Fixed payment arrangements, balloon payment amount									$ 15,000
Fixed payment arrangements, balloon payment amount, paid			$ 15,000
Fixed payment arrangements		$ 3,000				1,000
Fixed payment arrangements, quarterly payment amount, payments, number | payment								6
Fixed payment arrangements, quarterly payment amount								$ 500
(Gain) loss on debt extinguishment							$ 1,300
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Variable Payments
Other Commitments [Line Items]
Fixed payment arrangements, monthly variable payment amount, percentage of net revenue (as a percent)									15%
Fixed payment arrangements, monthly variable payment amount, minimum						100			$ 100
Fixed payment arrangements, monthly variable payment amount, one-time payment, paid				$ 200	$ 200
Fixed payment arrangements, monthly variable payment amount, aggregate payments to satisfy obligation if paid before 12 February 2026									9,300
Fixed payment arrangements, fixed, product minimum royalties per annum									$ 2,100
Fixed payment arrangements, payment amount, paid		$ 2,800
Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc
Other Commitments [Line Items]
Fixed payment arrangements						$ 6,700
Fixed payment arrangements, liability, reduction	$ 8,000
Fixed payment arrangements, installment payments, number | payment	3
Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc | Minimum
Other Commitments [Line Items]
Fixed payment arrangements	$ 6,000
Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc | Maximum
Other Commitments [Line Items]
Fixed payment arrangements	9,000
Fixed Payment Arrangements, TRIS Pharma, Inc, Royalty and Make Whole Payments
Other Commitments [Line Items]
Issues, fixed payment arrangements	$ 7,600

Other Liabilities - Supply and

Other Liabilities - Supply and Distribution Agreement (Details) - Supply and Distribution Agreement, Tris Pharma, Inc	12 Months Ended
	Jun. 30, 2022 USD ($) item
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Supply and distribution agreement, term	20 years
Supply and distribution agreement, royalty, percentage of net sales (as a percent)	23.50%
Supply and distribution agreement, minimum unit sales commitments, annual unit sales, units | item	70,000
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, per unit	$ 30
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, maximum annual amount	2,100,000
Supply and distribution agreement, commercial milestone obligations, cumulative net sales, maximum obligation	3,000,000
Supply and distribution agreement, commercial milestone obligations, net revenue trigger amount	$ 40,000,000

Other Liabilities - Contingent

Other Liabilities - Contingent Value Rights (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020	Feb. 29, 2020
Other Liabilities Disclosure [Abstract]
Contingent value rights, business combination, contingent consideration, milestone payable, amount, maximum	$ 5,000			$ 16,000
Contingent value rights, business combination, contingent consideration, milestone payable, shares, maximum (in shares)				470,000
Contingent Value Rights payouts (in shares)		103,190	123,820
Contingent value rights	578	$ 1,395
Contingent value rights, gain (loss) for change in fair value during period	$ 800	$ 3,200

Other Liabilities - Contingen_2

Other Liabilities - Contingent Consideration - Business Combination (Details) - Innovus Pharmaceuticals, Inc - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021	Feb. 29, 2020
Business Acquisition [Line Items]
Business combination, contingent consideration, license agreement, milestone payable, amount, every other year			$ 50
Business combination, contingent consideration, license agreement, milestone payable, amount			$ 200
Business combination, contingent consideration, license agreement, milestone payable, discount rate (as a percent)			26%
Business combination, contingent consideration, product related, milestone payable, amount			$ 200
Business combination, contingent consideration, product related, milestone payable, discount rate (as a percent)			30%
Contingent consideration	$ 400	$ 300

Other Liabilities - Contingen_3

Other Liabilities - Contingent Consideration - Other than Business Combination (Details) - USD ($) $ in Thousands		12 Months Ended
	May 12, 2022	Jun. 30, 2022	Jun. 30, 2021
Other Commitments [Line Items]
Contingent consideration other than from business combination, liability, reversed in period		$ 9,100
Other current liabilities		5,359	$ 8,347
Licensing Agreements, TRIS Pharma, Inc, Royalty and Make Whole Payments
Other Commitments [Line Items]
Contingent consideration other than from business combination, liability, reversed in period	$ 8,500
Contingent consideration other than from business combination, gain (loss) for change in fair value during period		(900)
Licensing Agreements, Magna Pharmaceuticals, Inc, ZolpiMist, Royalty Payments [Member]
Other Commitments [Line Items]
Contingent consideration other than from business combination, liability, reversed in period		600
Other current liabilities		50
Contingent consideration other than from business combination, gain (loss) for change in fair value during period		$ 600

Other Liabilities - Contingen_4

Other Liabilities - Contingent Consideration - Total (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Other Liabilities Disclosure [Abstract]
Business combination, contingent consideration, and contingent consideration other than from business combination, gain (loss) for change in fair value during period	$ (0.5)	$ (1.7)
Business combination, contingent consideration, and contingent consideration other than from business combination, accretion expense	$ 0.1	$ 0.4

Line of Credit (Details)

Line of Credit (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2022	Jan. 26, 2022	Jan. 25, 2022
Debt Instrument [Line Items]
Period of notice required before prepaying the debt instrument			5 days
Interest expense			$ 0.9
Legal and other fees			0.1
Aggregate borrowing capacity				$ 3.5	$ 1
Amortization of deferred financing costs			0.4
Other Noncurrent Assets [Member]
Debt Instrument [Line Items]
Unamortized debt issuance expense			$ 0.1
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 12.5	$ 25
Event Occurs on or before January 26, 2023 [Member]
Debt Instrument [Line Items]
Commitment fee percentage			2%
Event Occurs After January 26, 2023 But On or Before January 26, 2024 [Member]
Debt Instrument [Line Items]
Commitment fee percentage			1%
Event Occurs After January 26, 2024 But on or Before January 26, 2025 [Member]
Debt Instrument [Line Items]
Commitment fee percentage			0.50%
Neos Therapeutics, Inc [Member] | Loan Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 25
Maximum borrowing capacity portion available for short-term swingline loans	$ 2.5
Percentage of eligible accounts receivable against which short-term swingline loans may be made	85%
Unused capacity commitment fee percentage	0.50%
Interest expense		$ 0.2
Outstanding amount		$ 7.9	$ 3.8
Unused line of credit			$ 0.3
Neos Therapeutics, Inc [Member] | Loan Agreement | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Basis spread on variable rate	4.50%

Long-term Debt - Narrative (Det

Long-term Debt - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands			7 Months Ended	12 Months Ended
	Mar. 07, 2022	Jan. 26, 2022	Jan. 26, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 29, 2022	Mar. 31, 2021	Mar. 20, 2021
Debt Instrument [Line Items]
Carrying amount of the remaining outstanding debt		$ 600	$ 600
Gain (loss) on extinguishment of debt				$ 169	$ (1,569)
Debt Instrument, Interest Payment Term		18 months
Debt Instrument, Interest Payment Extension Term		6 months
Interest Only Period Further Extension Term		6 months
Debt Instrument, Term of Trailing Months Revenue		12 months
Debt Instrument Prepayment Fee Percentage		3%
Long-term, final payment fee				638
Loan Processing Fee				$ 400
Debt Instrument, Interest Rate, Effective Percentage				16.59%
Interest Expense, Debt				$ 900
Adjustments to Additional Paid in Capital, Warrant Issued				379
Avenue Capital Warrants [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.21	$ 1.21	$ 1.21
Warrants and Rights Outstanding		$ 600	$ 600
Share Price	$ 1.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	867,769
Adjustments to Additional Paid in Capital, Warrant Issued	$ 400
Minimum [Member] | Avenue Capital Warrants [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 1.21
Event Occurs After January 26, 2023 But On or Before January 26, 2024 [Member]
Debt Instrument [Line Items]
Debt Instrument Prepayment Fee Percentage		2%
Event Occurs After January 26, 2024 But on or Before January 26, 2025 [Member]
Debt Instrument [Line Items]
Debt Instrument Prepayment Fee Percentage		1%
Deerfield Facility
Debt Instrument [Line Items]
Carrying amount of the remaining outstanding debt							$ 16,600
Gain (loss) on extinguishment of debt				$ 200
Deerfield Facility | Neos Therapeutics, Inc [Member]
Debt Instrument [Line Items]
Fair value of the remaining outstanding debt								$ 17,400
Unamortized premium								$ 800
Interest expense			800
Avenue Capital Loan, Term Loan
Debt Instrument [Line Items]
Debt instrument, minimum variable rate before basis spread (as a percent)		3.25%
Debt instrument, basis spread on variable rate (as a percent)		7.40%
Face amount		$ 15,000	$ 15,000

Long-term Debt - Composition (D

Long-term Debt - Composition (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Debt Disclosure [Abstract]
Long-term debt, due on January 26, 2025	$ 15,000
Long-term, final payment fee	638
Unamortized discount	(1,443)
Financing leases, maturing through May 2024	180
Total debt	14,375
Less current portion	(96)	$ (16,668)
Non-current portion of debt	$ 14,279	$ 180

Long-term Debt - Future Princip

Long-term Debt - Future Principal Payments (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Debt Disclosure [Abstract]
2023	$ 96
2024	8,418
2025	7,304
Future principal payments	15,818
Less unamortized discount and issuance costs	(1,443)
Less current portion	(96)	$ (16,668)
Non-current portion of debt	$ 14,279	$ 180

Fair Value Measurements - Recur

Fair Value Measurements - Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Financial Liabilities Fair Value Disclosure [Abstract]
Contingent consideration	$ 396	$ 12,057
CVR liability	578	1,395
Fair Value, Recurring
Assets, Fair Value Disclosure [Abstract]
Cash and cash equivalents	19,360	49,649
Total	19,360	49,649
Financial Liabilities Fair Value Disclosure [Abstract]
Contingent consideration	396	12,057
CVR liability	578	1,395
Total	974	13,452
Fair Value, Recurring | Fair Value, Inputs, Level 1
Assets, Fair Value Disclosure [Abstract]
Cash and cash equivalents	19,360	49,649
Total	19,360	49,649
Fair Value, Recurring | Fair Value, Inputs, Level 3
Financial Liabilities Fair Value Disclosure [Abstract]
Contingent consideration	396	12,057
CVR liability	578	1,395
Total	$ 974	$ 13,452

Fair Value Measurements - Non-r

Fair Value Measurements - Non-recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Financial Liabilities Fair Value Disclosure [Abstract]
Fixed payment arrangements	$ 13,051	$ 9,458
Fair Value, Nonrecurring
Financial Liabilities Fair Value Disclosure [Abstract]
Fixed payment arrangements	13,051	9,458
Total	13,051	9,458
Fair Value, Nonrecurring | Fair Value, Inputs, Level 3
Financial Liabilities Fair Value Disclosure [Abstract]
Fixed payment arrangements	13,051	9,458
Total	$ 13,051	$ 9,458

Fair Value Measurements - Unobs

Fair Value Measurements - Unobservable Inputs Reconciliation, Recurring Basis, Liabilities - Tabular Disclosure (Details) $ in Thousands	12 Months Ended
	Jun. 30, 2022 USD ($)
Contingent Value Rights
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 1,395
Included in earnings	$ (817)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income	Gain (loss) from contingent consideration
Ending balance	$ 578
Contingent Consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	12,057
Included in earnings	$ 604
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income	Gain (loss) from contingent consideration
Settlements	$ (12,265)
Ending balance	396
Derivative Financial Instruments, Liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Included in earnings	$ (211)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income	Gain on derivative warrant liability
Issues	$ 590
Settlements	$ (379)

Fair Value Measurements - Uno_2

Fair Value Measurements - Unobservable Inputs Reconciliation, Recurring Basis, Liabilities - Additional Information (Details) $ in Thousands	12 Months Ended
	Jun. 30, 2022 USD ($)
Fair Value Disclosures [Abstract]
Contingent consideration other than from business combination, liability, reversed in period	$ 9,100
Fair value of warrants as additional paid in capital	$ 379

Fair Value Measurements - Uno_3

Fair Value Measurements - Unobservable Inputs Reconciliation, Non-recurring Basis, Liabilities (Details) $ in Thousands	12 Months Ended
	Jun. 30, 2022 USD ($)
Fair Value Disclosures [Abstract]
Beginning balance, fixed payment arrangements	$ 9,458
Included in earnings, fixed payment arrangements	1,148
Issues, fixed payment arrangements	7,645
Settlements, fixed payment arrangements	(5,200)
Ending balance, fixed payment arrangements	$ 13,051

Fair Value Measurements - Valua

Fair Value Measurements - Valuation Assumptions (Details)	Jun. 30, 2022	Jan. 26, 2022 Y	Jun. 30, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Valuation Technique		us-gaap:ValuationTechniqueOptionPricingModelMember
Measurement Input, Leveraged Beta
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.85		0.91
Measurement Input, Market Risk Premium
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.0622		0.0600
Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input		0.5675
Measurement Input, Expected Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input		5
Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.0286		0.0036
Derivative liability, measurement input		0.0166
Measurement Input, Discount Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.2050		0.1300
Measurement Input, Discount Rate | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fixed payment arrangements, measurement input	0.100		0.100
Measurement Input, Discount Rate | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fixed payment arrangements, measurement input	0.154		0.124
Measurement Input, Discount for Lack of Marketability
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.1000		0.0500
Measurement Input, Expected Dividend Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input		0

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Current Income Tax Expense (Benefit), Continuing Operations [Abstract]
State	$ 7	$ 16
Total current tax expense	7	16
Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]
Federal	(91)	200
State	(26)	43
Total deferred tax expense	(117)	243
Provision for income taxes	$ (110)	$ 259

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Income Tax Provision (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Tax at statutory rate	$ (23,159)	$ (12,185)
State income taxes, net of federal benefit	601	(2,461)
Stock based compensation	273	43
Contingent consideration	(155)	(667)
162(m) limitation	76	235
Goodwill impairment	9,733
Transaction costs		160
Change in valuation allowance	12,472	14,483
Other	49	651
Provision for income taxes	$ (110)	$ 259
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Tax at statutory rate (as a percent)	(21.00%)	(21.00%)
State income taxes, net of federal benefit (as a percent)	0.55%	(4.24%)
Stock based compensation (as a percent)	0.27%	0.07%
Contingent consideration (as a percent)	(0.14%)	(1.15%)
162(m) limitation (as a percent)	0.08%	0.40%
Goodwill impairment (as a percent)	8.83%
Transaction costs (as a percent)		0.28%
Change in valuation allowance (as a percent)	11.31%	24.96%
Other (as a percent)	0.01%	1.13%
Net income tax provision (benefit) (as a percent)	(0.09%)	0.45%

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Liabilities - Tabular Disclosure (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Deferred Tax Assets, Net of Valuation Allowance [Abstract]
Net operating loss carry forward	$ 114,443	$ 106,712
Accrued Rebates	5,944	8,412
Share-based compensation	2,773	2,330
Accrued expenses	817	1,507
R&D credits	2,423	2,115
Interest	2,975	2,064
Inventory	1,177	1,704
Lease liability	799	1,031
Other	1,301	1,526
Total deferred tax assets	132,652	127,401
Less: valuation allowance	(128,966)	(116,494)
Deferred tax assets, net of valuation allowance	3,686	10,907
Deferred Tax Liabilities, Net [Abstract]
Intangibles	(2,717)	(9,396)
ROU asset	(308)	(1,009)
Fixed assets	(788)	(745)
Total deferred tax liabilities	(3,813)	(11,150)
Net deferred tax liabilities	$ (127)	$ (243)

Income Taxes - Deferred Tax A_2

Income Taxes - Deferred Tax Assets and Liabilities - Additional Information (Details) $ in Millions	12 Months Ended
	Jun. 30, 2022 USD ($)
Income Tax Disclosure [Abstract]
Goodwill impairment, decrease in net deferred tax liabilities	$ 0.1
Income tax benefit resulting from decreased net deferred tax liabilities	$ 0.1

Income Taxes - Deferred Tax A_3

Income Taxes - Deferred Tax Assets and Liabilities - Balance Sheet Location (Details) $ in Millions	Jun. 30, 2022 USD ($)
Other Noncurrent Liabilities
Liabilities, Other than Long-term Debt, Noncurrent [Abstract]
Deferred tax liabilities	$ 0.1

Income Taxes - Operating Loss C

Income Taxes - Operating Loss Carry Forwards (Details) - Domestic Tax Authority - USD ($) $ in Millions	Jun. 30, 2022	Jun. 30, 2021
Operating Loss Carryforwards [Line Items]
Net operating losses	$ 503.2	$ 466.7
Operating loss carryforwards not subject to expiration	$ 171.5

Income Taxes - Tax Credit Carry

Income Taxes - Tax Credit Carry Forwards (Details) $ in Millions	Jun. 30, 2022 USD ($)
Research Tax Credit Carryforward
Tax Credit Carryforward [Line Items]
Tax credit carry forward	$ 3

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits - General Information (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Unrecognized tax benefits	$ 9,833	$ 11,537	$ 0

Income Taxes - Unrecognized T_2

Income Taxes - Unrecognized Tax Benefits - Roll Forward (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning balance	$ 11,537	$ 0
Increase resulting from prior period tax positions		12,017
Increase resulting from current period tax positions		2
Decrease resulting from current period tax positions	(1,704)	(482)
Ending balance	$ 9,833	$ 11,537

Stockholders Equity - Common an

Stockholders Equity - Common and Preferred Stock (Details) - $ / shares	Jun. 30, 2022	Jun. 30, 2021
Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares issued (in shares)	38,578,825	27,490,412
Common stock, shares outstanding (in shares)	38,578,825	27,490,412
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Stockholders Equity - Restricte

Stockholders Equity - Restricted Stock (Details) - shares	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares outstanding (in shares)	38,578,825	27,490,412
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares outstanding (in shares)	1,707,730

Stockholders Equity - Stock Off

Stockholders Equity - Stock Offerings (Details) - USD ($) $ / shares in Units, $ in Millions		12 Months Ended
	Mar. 07, 2022	Jun. 30, 2022	Oct. 07, 2021	Jun. 17, 2021	Jun. 04, 2021
Shelf Registration Statement, 2020 Shelf
Subsidiary, Sale of Stock [Line Items]
Shelf registration, amount authorized				$ 100
Shelf registration, remaining amount available for sale		$ 43
Shelf Registration Statement, 2020 Shelf, At-the-market Sales Agreement
Subsidiary, Sale of Stock [Line Items]
At-the-market sales agreement, amount authorized					$ 30
At-the-market sales agreement, remaining amount available for sale		$ 12.2
Issuance of common stock (in shares)		2,430,784
Proceeds from issuance of common stock		$ 5.1
Underwriting discounts, commissions, and other offering expenses		0.2
Shelf Registration Statement, 2021 Shelf
Subsidiary, Sale of Stock [Line Items]
Shelf registration, amount authorized			$ 100
Shelf registration, remaining amount available for sale		$ 92.4
Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, March 2022
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares)	3,030,000
Share price (in dollars per share)	$ 1.25
Proceeds from issuance of common stock and warrants	$ 7.6
Commission and other costs	$ 0.8

Stockholders Equity - Warrants

Stockholders Equity - Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Mar. 07, 2022	Jan. 26, 2022	Jun. 30, 2022	Sep. 07, 2022
Class of Warrant or Right [Line Items]
Fair value of warrants as additional paid in capital			$ 379
Warrants to Purchase Common Stock, Equity Classified, March 2022
Class of Warrant or Right [Line Items]
Fair value of warrants	$ 6,300
Warrants to Purchase Common Stock, Equity Classified, Pre-funded Warrants, March 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	3,030,000
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 0.0001
Warrants to Purchase Common Stock, Equity Classified, Common Warrants, March 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	6,666,000
Class of warrant or right, number of securities called by each warrant or right (in shares)	1.1
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 1.30
Class of warrant or right, date from which warrants or rights exercisable	Sep. 07, 2022
Warrants and rights outstanding, term	5 years			5 years
Warrants to Purchase Common Stock, Equity Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	867,769
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 1.21
Fair value of warrants as additional paid in capital	$ 400
Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 1.21
Class of warrant or right, date from which warrants or rights exercisable		Jan. 26, 2022

Equity Incentive Plans - Genera

Equity Incentive Plans - General Information (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Apr. 19, 2021	Mar. 31, 2021	Feb. 13, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	80,377	109,588
Non-option equity instruments, Granted (in shares)	0
Weighted-average grant date fair value of options granted	$ 0	$ 3.81
Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs, options	$ 0.2
Unrecognized compensation costs, period for recognition	1 year 7 months 6 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested units outstanding (in shares)	1,607,572	1,955,268
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested units outstanding (in shares)	170,000	78,318
Unrecognized compensation costs, period for recognition	2 years 7 months 6 days
Total fair value	$ 0.1
Aytu 2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)					5,000,000
Number of shares available for grant (in shares)	2,383,061
Aytu 2015 Plan | Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award	10 years
Aytu 2015 Plan | Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Aytu 2015 Plan | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Aytu 2015 Plan | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs, period for recognition	2 years 8 months 12 days
Total fair value	$ 1.6
Aytu 2015 Plan | Restricted Stock [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Aytu 2015 Plan | Restricted Stock [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	10 years
Aytu 2015 Plan | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Neos 2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)				69,721
Number of shares available for grant (in shares)	45,294		105,449
Neos 2015 Plan | Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award	10 years
Neos 2015 Plan | Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Neos 2015 Plan | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Neos 2015 Plan | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested units outstanding (in shares)				35,728

Equity Incentive Plans - Stock

Equity Incentive Plans - Stock Option Activity (Details) - $ / shares	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2020
Number of Options
Number of options outstanding, beginning balance (in shares)	109,588
Forfeited/cancelled (in shares)	(15,569)
Expired (in shares)	(13,642)
Number of options outstanding, ending balance (in shares)	80,377
Weighted Average Exercise Price
Weighted average exercise price outstanding, beginning balance (in dollars per share)	$ 14.52
Forfeited/cancelled (in dollars per share)	7.98
Expired (in dollars per share)	9.65
Weighted average exercise price outstanding, ending balance (in dollars per share)	$ 16.61
Additional information
Outstanding, weighted average remaining contractual life (Year)	7 years 9 months 7 days	8 years 25 days
Number of options exercisable	54,649
Weighted average exercise price exercisable (in dollars per share)	$ 20.58
Weighted average remaining contractual life in years exercisable	7 years 9 months 7 days

Equity Incentive Plans - Range

Equity Incentive Plans - Range of Exercise Prices (Details)	12 Months Ended
	Jun. 30, 2022 $ / shares shares
Equity Incentive Plan
Number of options outstanding | shares	80,377
Weighted average exercise price	$ 16.61
Weighted average remaining contractual life of options outstanding	7 years 9 months 7 days
Number of options exercisable | shares	54,649
Weighted average exercise price	$ 20.58
Exercise Price Range 1
Equity Incentive Plan
Number of options outstanding | shares	38,998
Weighted average exercise price	$ 6.44
Weighted average remaining contractual life of options outstanding	7 years 7 months 24 days
Number of options exercisable | shares	19,882
Weighted average exercise price	$ 6.50
Exercise Price Range 1 | Minimum [Member]
Equity Incentive Plan
Range of exercise prices	6.2
Exercise Price Range 1 | Maximum [Member]
Equity Incentive Plan
Range of exercise prices	$ 9.70
Exercise Price Range 2
Equity Incentive Plan
Number of options outstanding | shares	41,225
Weighted average exercise price	$ 14.13
Weighted average remaining contractual life of options outstanding	7 years 10 months 24 days
Number of options exercisable | shares	34,613
Weighted average exercise price	$ 14.28
Exercise Price Range 2 | Minimum [Member]
Equity Incentive Plan
Range of exercise prices	9.80
Exercise Price Range 2 | Maximum [Member]
Equity Incentive Plan
Range of exercise prices	$ 14.70
Exercise Price Range 3
Equity Incentive Plan
Number of options outstanding | shares	154
Weighted average exercise price	$ 3,255.06
Weighted average remaining contractual life of options outstanding	3 years 9 months 18 days
Number of options exercisable | shares	154
Weighted average exercise price	$ 3,255.06
Exercise Price Range 3 | Minimum [Member]
Equity Incentive Plan
Range of exercise prices	2,800
Exercise Price Range 3 | Maximum [Member]
Equity Incentive Plan
Range of exercise prices	$ 4,200

Equity Incentive Plans - Restri

Equity Incentive Plans - Restricted Stock - General Information (Details) - Restricted Stock [Member] - $ / shares			12 Months Ended
	Aug. 02, 2021	Jun. 01, 2015	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested units outstanding (in shares)			1,607,572	1,955,268
Granted (in shares)		158	295,000
Granted, weighted average grant date fair value (in dollars per share)			$ 3.67
Aytu 2015 Plan | Management
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	295,000
Aytu 2015 Plan | Management | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, weighted average grant date fair value (in dollars per share)			2.65
Aytu 2015 Plan | Management | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, weighted average grant date fair value (in dollars per share)			$ 4.02
Aytu 2015 Plan | Management | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	33.33%
Aytu 2015 Plan | Management | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Five
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Six
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Seven
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Eight
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Nine
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	8.33%

Equity Incentive Plans - Rest_2

Equity Incentive Plans - Restricted Stock - Activity (Details) - Restricted Stock [Member] - $ / shares		12 Months Ended
	Jun. 01, 2015	Jun. 30, 2022
Number of Shares
Unvested outstanding, beginning balance (in shares)		1,955,268
Granted (in shares)	158	295,000
Vested (in shares)		(642,696)
Unvested outstanding, ending balance (in shares)		1,607,572
Weighted Average Grant Date Fair Value
Unvested, weighted average grant date fair value outstanding, beginning balance (in dollars per share)		$ 7.83
Granted (in dollars per share)		3.67
Vested (in dollars per share)		6.81
Unvested, weighted average grant date fair value outstanding, ending balance (in dollars per share)		$ 7.47

Equity Incentive Plans - Rest_3

Equity Incentive Plans - Restricted Stock - Additional Information (Details) - Restricted Stock [Member] - $ / shares			12 Months Ended
	Jan. 17, 2022	Jun. 01, 2015	Jun. 30, 2022	Jun. 30, 2021
Equity Incentive Plan
Unvested units outstanding (in shares)			1,607,572	1,955,268
Granted (in shares)		158	295,000
Granted, weighted average grant date fair value (in dollars per share)			$ 3.67
Non-plan | Management
Equity Incentive Plan
Granted (in shares)	100,000
Granted, weighted average grant date fair value (in dollars per share)	$ 1.35
Non-plan | Management | Tranche One
Equity Incentive Plan
Vesting percentage	33.33%
Non-plan | Management | Tranche Two
Equity Incentive Plan
Vesting percentage	8.33%
Non-plan | Management | Tranche Three
Equity Incentive Plan
Vesting percentage	8.33%
Non-plan | Management | Tranche Four
Equity Incentive Plan
Vesting percentage	8.33%
Non-plan | Management | Tranche Five
Equity Incentive Plan
Vesting percentage	8.33%
Non-plan | Management | Tranche Six
Equity Incentive Plan
Vesting percentage	8.33%
Non-plan | Management | Tranche Seven
Equity Incentive Plan
Vesting percentage	8.33%
Non-plan | Management | Tranche Eight
Equity Incentive Plan
Vesting percentage	8.33%

Equity Incentive Plans - Rest_4

Equity Incentive Plans - Restricted Stock Unit - General Information (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares		12 Months Ended
	Dec. 01, 2021	Jun. 30, 2022
Equity Incentive Plan
Granted (in shares)		170,000
Granted, weighted average grant date fair value (in dollars per share)		$ 1.29
Aytu 2015 Plan | Management
Equity Incentive Plan
Granted (in shares)	170,000
Aytu 2015 Plan | Management | Minimum [Member]
Equity Incentive Plan
Granted, weighted average grant date fair value (in dollars per share)		1.06
Aytu 2015 Plan | Management | Maximum [Member]
Equity Incentive Plan
Granted, weighted average grant date fair value (in dollars per share)		$ 1.86
Aytu 2015 Plan | Management | Tranche One
Equity Incentive Plan
Vesting percentage	33.33%
Aytu 2015 Plan | Management | Tranche Two
Equity Incentive Plan
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Three
Equity Incentive Plan
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Four
Equity Incentive Plan
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Five
Equity Incentive Plan
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Six
Equity Incentive Plan
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Seven
Equity Incentive Plan
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Eight
Equity Incentive Plan
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Nine
Equity Incentive Plan
Vesting percentage	8.33%

Equity Incentive Plans - Rest_5

Equity Incentive Plans - Restricted Stock Unit - Activity (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Jun. 30, 2022 $ / shares shares
Number of Shares
Unvested outstanding, beginning balance (in shares) | shares	78,318
Granted (in shares) | shares	170,000
Vested (in shares) | shares	(15,396)
Forfeited (in shares) | shares	(62,922)
Unvested outstanding, ending balance (in shares) | shares	170,000
Weighted Average Grant Date Fair Value
Unvested, weighted average grant date fair value outstanding, beginning balance (in dollars per share) | $ / shares	$ 7.20
Granted (in dollars per share) | $ / shares	1.29
Vested | $ / shares	6.20
Forfeited (in dollars per share) | $ / shares	7.44
Unvested, weighted average grant date fair value outstanding, ending balance (in dollars per share) | $ / shares	$ 1.29

Equity Incentive Plans - Unreco

Equity Incentive Plans - Unrecognized Compensation Costs (Details) $ in Millions	12 Months Ended
	Jun. 30, 2022 USD ($)
Share-Based Payment Arrangement, Option [Member]
Unrecognized compensation costs
Unrecognized compensation costs, options	$ 0.2
Unrecognized compensation costs, period for recognition	1 year 7 months 6 days
Restricted Stock [Member] | Aytu 2015 Plan
Unrecognized compensation costs
Unrecognized compensation costs, excluding options	$ 9.6
Unrecognized compensation costs, period for recognition	2 years 8 months 12 days
Restricted Stock [Member] | Non-plan
Unrecognized compensation costs
Unrecognized compensation costs, excluding options	$ 0.9
Unrecognized compensation costs, period for recognition	3 years 4 months 24 days
Restricted Stock Units (RSUs) [Member]
Unrecognized compensation costs
Unrecognized compensation costs, excluding options	$ 0.2
Unrecognized compensation costs, period for recognition	2 years 7 months 6 days

Equity Incentive Plans - Stock-

Equity Incentive Plans - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Stock-based compensation expense
Total share-based compensation expense	$ 5,248	$ 3,574
Cost of Sales
Stock-based compensation expense
Total share-based compensation expense	31	16
Research and development
Stock-based compensation expense
Total share-based compensation expense	536	68
Selling and Marketing
Stock-based compensation expense
Total share-based compensation expense	24	27
General and Administrative
Stock-based compensation expense
Total share-based compensation expense	$ 4,657	$ 3,463

Warrants - Stock Issued (Detail

Warrants - Stock Issued (Details) - Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, March 2022	Mar. 07, 2022 $ / shares shares
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares) | shares	3,030,000
Share price (in dollars per share) | $ / shares	$ 1.25

Warrants - General Information

Warrants - General Information (Details) - $ / shares			12 Months Ended
	Mar. 07, 2022	Jan. 26, 2022	Jun. 30, 2022	Sep. 07, 2022	Jun. 30, 2021
Warrants to Purchase Common Stock, Equity Classified
Class of Warrant or Right [Line Items]
Warrants expired (in shares)			124,250
Outstanding warrants (in shares)			8,664,471		1,254,952
Warrants to Purchase Common Stock, Equity Classified | Weighted Average
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)			$ 4.63		$ 35.85
Warrants expired (in dollars per share)			$ 124.69
Warrants to Purchase Common Stock, Equity Classified, Pre-funded Warrants, March 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	3,030,000
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 0.0001
Warrants to Purchase Common Stock, Equity Classified, Common Warrants, March 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	6,666,000
Class of warrant or right, number of securities called by each warrant or right (in shares)	1.1
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 1.30
Class of warrant or right, date from which warrants or rights exercisable	Sep. 07, 2022
Warrants and rights outstanding, term	5 years			5 years
Warrants to Purchase Common Stock, Equity Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	867,769
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 1.21
Warrants to Purchase Common Stock, Liability Classified
Class of Warrant or Right [Line Items]
Outstanding warrants (in shares)			24,105		24,105
Warrants to Purchase Common Stock, Liability Classified | Weighted Average
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)			$ 720		$ 720
Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 1.21
Class of warrant or right, date from which warrants or rights exercisable		Jan. 26, 2022

Warrants - Valuation Assumption

Warrants - Valuation Assumptions (Details) - Warrants to Purchase Common Stock, Equity Classified	Mar. 07, 2022 Y
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, valuation technique	us-gaap:ValuationTechniqueOptionPricingModelMember
Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.5445
Measurement Input, Expected Term | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	4.89
Measurement Input, Expected Term | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	5
Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.0171
Measurement Input, Expected Dividend Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0

Warrants - Equity-based Warrant

Warrants - Equity-based Warrants Activity (Details) - Warrants to Purchase Common Stock, Equity Classified - $ / shares	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Class of Warrant or Right [Line Items]
Outstanding, number of warrants (in shares)	1,254,952
Warrants issued (in shares)	10,563,769
Warrants exercised (in shares)	(3,030,000)
Warrants expired (in shares)	(124,250)
Outstanding, number of warrants (in shares)	8,664,471	1,254,952
Outstanding, weighted average remaining contractual life	4 years 8 months 23 days	2 years 9 months 29 days
Warrants issued, weighted average remaining contractual life	5 years 1 month 13 days
Weighted Average
Class of Warrant or Right [Line Items]
Outstanding, exercise price (in dollars per share)	$ 35.85
Warrants issued (in dollars per share)	0.92
Warrants exercised (in dollars per share)	0
Warrants expired (in dollars per share)	124.69
Outstanding, exercise price (in dollars per share)	$ 4.63	$ 35.85

Employee Benefit Plan (Details)

Employee Benefit Plan (Details) $ in Millions	12 Months Ended
	Jun. 30, 2022 USD ($) plan	Jun. 30, 2021 USD ($)
Employee Benefit Plan
Number of employee benefit plan | plan	2
Neos Plan
Employee Benefit Plan
Employee benefit plan contribution	$ 0.4	$ 0.1
Neos Plan | First 3% Contribution by Employees
Employee Benefit Plan
Percentage employer matches of employee's contribution	100%
Percentage of employees' salary with employer matching contribution	3%
Neos Plan | Next 4% and 5% Contribution by Employees
Employee Benefit Plan
Percentage employer matches of employee's contribution	50%
Neos Plan | Next 4% Contribution by Employees
Employee Benefit Plan
Percentage of employees' salary with employer matching contribution	4%
Neos Plan | Next 5% Contribution by Employees
Employee Benefit Plan
Percentage of employees' salary with employer matching contribution	5%
Aytu Plan
Employee Benefit Plan
Employee benefit plan contribution	$ 0.2	$ 0.2
Aytu Plan | 6% Contribution By Employees
Employee Benefit Plan
Percentage employer matches of employee's contribution	50%
Percentage of employees' salary with employer matching contribution	6%

Commitments and Contingencies -

Commitments and Contingencies - Fixed Payment Arrangements (Details) $ in Thousands				1 Months Ended		12 Months Ended
	May 12, 2022 USD ($)	Jun. 21, 2021 USD ($)	May 29, 2020 USD ($)	Jan. 31, 2021 USD ($)	Jan. 31, 2020 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2021 USD ($) payment	Jun. 30, 2021 USD ($)	Nov. 01, 2019 USD ($) agreement
Other Commitments [Line Items]
Fixed payment arrangements						$ 13,051		$ 9,458
Issues, fixed payment arrangements						7,645
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc
Other Commitments [Line Items]
Fixed payment arrangements, periodic payment obligations, number | agreement									2
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Fixed Payments
Other Commitments [Line Items]
Fixed payment arrangements, monthly payment amount									$ 100
Fixed payment arrangements, balloon payment amount									15,000
Fixed payment arrangements, balloon payment amount, paid			$ 15,000
Fixed payment arrangements		$ 3,000				1,000
Fixed payment arrangements, quarterly payment amount, payments, number | payment							6
Fixed payment arrangements, quarterly payment amount							$ 500
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Variable Payments
Other Commitments [Line Items]
Fixed payment arrangements, monthly variable payment amount, minimum						100			$ 100
Fixed payment arrangements, monthly variable payment amount, one-time payment, paid				$ 200	$ 200
Fixed payment arrangements, payment amount, paid		$ 2,800
Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc
Other Commitments [Line Items]
Fixed payment arrangements						$ 6,700
Fixed Payment Arrangements, TRIS Pharma, Inc, Royalty and Make Whole Payments
Other Commitments [Line Items]
Issues, fixed payment arrangements	$ 7,600

Commitments and Contingencies_2

Commitments and Contingencies - Supply and Distribution Agreement (Details) - Supply and Distribution Agreement, Tris Pharma, Inc	12 Months Ended
	Jun. 30, 2022 USD ($) item
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Supply and distribution agreement, term	20 years
Supply and distribution agreement, royalty, percentage of net sales (as a percent)	23.50%
Supply and distribution agreement, minimum unit sales commitments, annual unit sales, units | item	70,000
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, per unit	$ 30
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, maximum annual amount	2,100,000
Supply and distribution agreement, commercial milestone obligations, cumulative net sales, maximum obligation	3,000,000
Supply and distribution agreement, commercial milestone obligations, net revenue trigger amount	$ 40,000,000

Commitments and Contingencies_3

Commitments and Contingencies - Contingent Consideration Liability (Details) - USD ($) $ in Millions		12 Months Ended
	May 12, 2022	Jun. 30, 2022
Other Commitments [Line Items]
Contingent consideration other than from business combination, liability, reversed in period		$ 9.1
Licensing Agreements, TRIS Pharma, Inc, Royalty and Make Whole Payments
Other Commitments [Line Items]
Contingent consideration other than from business combination, liability, reversed in period	$ 8.5
Contingent consideration other than from business combination, gain (loss) for change in fair value during period		$ (0.9)

Commitments and Contingencies_4

Commitments and Contingencies - Product Contingent Liability (Details) $ in Thousands	Jul. 01, 2021 USD ($)	Feb. 28, 2015 USD ($) payment
Product Contingent Liability, Novalere, FlutiCare
Other Commitments [Line Items]
Product contingent liability, additional payments, number, certain sales achieved | payment		5
Product contingent liability, additional payments, amount, certain sales achieved		$ 500
Product Contingent Liability, UIRD
Other Commitments [Line Items]
Product contingent liability, milestone, payment, every other year	$ 50
Product contingent liability, milestone, payment	200
Other commitment	100
Product contingent liability, milestone, paid	$ 50

Commitments and Contingencies_5

Commitments and Contingencies - Earn Out Payments (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Apr. 12, 2021
Commercial Global License Agreements, AR101
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, milestone, maximum earn-out, cash and common stock		$ 67,500
License agreement, milestone payment paid, cash and common stock	$ 4,000
Issuance of common stock related to milestone payment (in shares)	2,188,940
License agreement, milestone payment paid, cash	$ 2,600
Commercial Global License Agreement, Denovo Biopharma LLC, AR101
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, annual maintenance fee		25
License agreement, license option fee		600
License agreement, escalating royalties, maximum		101,700
Commercial Global License Agreement, Johns Hopkins University, AR101
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, minimum annual royalties, low end of range		5
License agreement, minimum annual royalties, high end of range		$ 20
License agreement, royalties, percentage of net product sales (as a percent)		3%
License agreement, royalties, achievement of certain regulatory and commercial milestones, maximum		$ 1,600

License Agreements (Details)

License Agreements (Details) - USD ($) $ in Millions	1 Months Ended
	Apr. 30, 2020	Oct. 31, 2017	Feb. 29, 2016
Licensing Agreement, Cedars-Sinai Medical Center, Healight
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, term, after the first bona fide commercial sale of such licensed product in a country	10 years
License agreement, initial license fee paid	$ 0.3
License agreement, patent prosecution fees paid	$ 0.1
Settlement Agreement and Associated License Agreement, 2014, Shire LLC, New Drug Application
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, up-front, non-refundable license fee paid, maximum			$ 1
License Agreement, 2017, Shire LLC, New Drug Application
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, up-front, non-refundable license fee paid, maximum		$ 1

Segment Information - General I

Segment Information - General Information (Details) - segment	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of reportable segments	2	2

Segment Information - Impairmen

Segment Information - Impairment (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Asset Impairment Charges [Abstract]
Impairment loss	$ 75,458	$ 12,825
BioPharma
Asset Impairment Charges [Abstract]
Impairment loss	64,600
Consumer Health
Asset Impairment Charges [Abstract]
Impairment loss	$ 10,800

Segment Information - Consolida

Segment Information - Consolidated Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Revenues [Abstract]
Revenue from contract with customer	$ 96,669	$ 65,632
BioPharma
Revenues [Abstract]
Revenue from contract with customer	61,121	32,678
Consumer Health
Revenues [Abstract]
Revenue from contract with customer	$ 35,548	$ 32,954

Segment Information - Consoli_2

Segment Information - Consolidated Net Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting Information, Profit (Loss) [Abstract]
Net loss	$ (110,173)	$ (58,289)
BioPharma
Segment Reporting Information, Profit (Loss) [Abstract]
Net loss	(92,708)	(50,529)
Consumer Health
Segment Reporting Information, Profit (Loss) [Abstract]
Net loss	$ (17,465)	$ (7,760)

Segment Information - Total Ass

Segment Information - Total Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Assets [Abstract]
Assets	$ 137,623	$ 265,668
BioPharma
Assets [Abstract]
Assets	121,377	236,449
Consumer Health
Assets [Abstract]
Assets	$ 16,246	$ 29,219

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event $ in Millions	1 Months Ended
	Aug. 31, 2022 USD ($) shares
Warrants to Purchase Common Stock, Equity Classified, Common Warrants, August 2022
Subsequent Event [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	1,750,000
Warrants to Purchase Common Stock, Equity Classified, Pre-funded Warrants, August 2022
Subsequent Event [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	23,255,814
Underwritten Public Offering, August 2022
Subsequent Event [Line Items]
Issuance of common stock (in shares)	21,505,814
Proceeds from issuance of common stock and warrants | $	$ 10
Proceeds from issuance of common stock and warrants, net of issuance costs | $	$ 9.1